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In 2016, The Mid North Coast Cancer Institute (MNCCI) implemented Elekta’s Monaco® electron 
Monte Carlo (eMC) dose calculation algorithm for electron beams. The new algorithm resulted in a 
change in clinical practice whereby monitor units (MU) delivered to patients would be calculated in 
terms of dose to medium (𝐷𝑚), rather than using measured, dose to water (𝐷𝑤)-based MU. 
Delivering high energy ionising radiation during radiotherapy has inherent risks. Therefore, it is crucial 
to patient safety that dose calculations performed by the treatment planning system (TPS) are 
accurate. Any changes in clinical practice should also be understood in terms of their effect on patient 
outcomes (both tumour control and normal tissue toxicity). This research aims to validate the 
accuracy of the 𝐷𝑚-based MU calculated by the Elekta Monaco® eMC algorithm and to assess 
patient outcomes in terms of acute skin toxicity due to this change in clinical practice.  
To validate the 𝐷𝑚-based MU, the dose measured with an ionisation chamber was compared with 
the dose calculated by the Elekta Monaco® eMC algorithm in a range of clinically relevant phantoms. 
The assessment of acute toxicity involved a cohort study that compared acute skin toxicity grades of 
skin cancer patients treated before the change in clinical practice (cohort 1) and after the change 
(cohort 2). Various predictors of radiation-induced acute skin toxicity were also investigated.  
The comparison between measured and calculated dose found that the Elekta Monaco® eMC 𝐷𝑚 
calculation is accurate in most clinical scenarios. The level of agreement between the measured and 
calculated 𝐷𝑚 data is mostly within ± 3.5% for a wide range of tissue types. However, for tissues 
xv 
 
with densities significantly different from water (i.e. < 0.5 g/cm3 and > 1.5 g/cm3), the method used to 
determine 𝐷𝑚 from measurements of ionisation resulted in unacceptable levels of uncertainty. For 
these tissues, a more accurate validation method, such as full Monte Carlo modelling, is required. 
Two hundred and ninety-four patients were recruited into the cohort study, with 141 patients in cohort 
1 and 153 patients in cohort 2. Statistical analysis of patient acute toxicity data was performed using 
the Cochran-Armitage test for linear trend and binary logistic regression modelling. 
The results of the Cochran-Armitage test for linear trend found no statistically significant increase in 
acute skin toxicity for patients in cohort 2 compared with patients in cohort 1. Therefore, the change 
in clinical practice from using the measured 𝐷𝑤-based MU to using the 𝐷𝑚-based MU as calculated 
in the Elekta Monaco® eMC algorithm does not increase acute skin toxicity for skin cancer patients 
treated with electron beams. 
Binary logistic regression modelling found a statistically significant correlation between baseline 
toxicity grade and acute toxicity grade, suggesting that baseline grade is often a predictor of acute 
toxicity grade. This modelling also found that patients treated with the 𝐷𝑚-based MU as calculated 
in the Elekta Monaco® eMC algorithm experience statistically significant lower levels of pain, while 
those patients with treatment sites involving bone experience statistically significant lower levels of 
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Cancer is a leading cause of mortality in Australia with close to 50,000 deaths estimated for 2019 
(Australian Institute of Health and Welfare 2019). It is expected that 150,000 new cases of cancer 
will be diagnosed in Australia in 2020, representing an increase of almost 40% since 2007 (Australian 
Institute of Health and Welfare 2012). Radiotherapy is a common form of treatment, used in 
approximately 50% of notifiable cancer cases in Australia (Ingham Institute for Applied Medical 
Research 2013), either with curative intent or for palliation. It uses high energy ionising radiation to 
damage the DNA of cancer cells, ultimately leading to cell death. 
An essential component of a modern-day radiotherapy department is the treatment planning system 
(TPS). A TPS allows planners to tailor treatments to the specific anatomy of the patient and design 
beam arrangements to maximise radiation damage to the tumour volume while sparing normal tissue. 
However, high energy ionising radiation has inherent risks. It is crucial, therefore, to patient safety 
that the dose calculations performed by the TPS are accurate. Furthermore, dose calculations play 
a critical role in optimising the therapeutic gain by maximising the tumour control probability (TCP) 
while minimising the normal tissue complication probability (NTCP). In fact, studies have shown that 
a 5% change in dose can result in a 10% - 20% change in TCP or up to a 20% - 30% change in 
NTCP (Chetty et al. 2007; Goitein & Busse 1975; Stewart & Jackson 1975).  
Dose calculation algorithms for electron beams have evolved dramatically over the years: from 
rudimentary broad beam approaches to pencil beam techniques, and, more recently, to Monte Carlo 
methods. Monte Carlo-based algorithms are increasingly used for their superior calculation accuracy, 
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particularly in inhomogeneous tissue, as compared with analytic dose algorithms. A major implication 
of Monte Carlo-based treatment planning systems is that doses can be calculated with respect to the 
actual tissue in which they are deposited i.e. dose to medium (𝐷𝑚). 
To improve treatment accuracy, in 2016, The Mid North Coast Cancer Institute (MNCCI) implemented 
Elekta’s Monaco® electron Monte Carlo (eMC) dose calculation algorithm for electron beams. Upon 
initial clinical implementation, the monitor units (MU) delivered to the patient were based on a cut-out 
factor measurement in plastic water, according to previous MNCCI practice. However, from 
approximately May 2018, clinical practice changed whereby the 𝐷𝑚-based MU as calculated in the 
Elekta Monaco® eMC algorithm were used for all patient treatments. 
MNCCI staff noted the number of MU calculated in the Elekta Monaco® eMC algorithm in terms of 
𝐷𝑚 were higher, on average, compared with the MU based on measurements in plastic water. For 
some treatment sites involving significant tissue inhomogeneities, large differences (of approximately 
10%) were observed, similar to that reported in the literature (Cygler et al. 2005). Some radiation 
oncologists at MNCCI queried whether the magnitude of these differences in MU would clinically 
affect patient outcomes. 
Acute toxicity is one radiobiological measure that can be used to judge the effect of this change in 
clinical practice. Acute toxicity results from the death of a large number of cells and occurs within a 
few days or weeks after irradiation. Many studies have investigated the severity of acute toxicity due 
to various changes in clinical practice (Lin et al. 2018; McDonald et al. 2016). However, to date, little 
work has been carried out to assess acute skin toxicity variations when changing to a Monte Carlo 
𝐷𝑚-based treatment planning approach for clinical electron beams. Given the differences between 
the 𝐷𝑚-based MU as calculated in the Elekta Monaco® eMC algorithm and those derived from water-
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based measurement, a clinically observable increase in acute skin toxicity due to this change in 
clinical practice is plausible.  
To address the queries raised by the radiation oncologists, this research project aims to answer two 
key research questions. 
Research question 1: Are the 𝐷𝑚-based MU as calculated in the Elekta Monaco® eMC algorithm 
accurate in a range of clinically relevant settings? 
Research question 2: Is there a clinically observable increase in acute skin toxicity for electron 
patients treated with the Elekta Monaco® eMC 𝐷𝑚-based MU as compared with a similar cohort of 
patients treated with the measured dose to water (𝐷𝑤)-based MU? 
Both Chapter 3 and Chapter 4 address research question 1. Chapter 3 investigates the ability of the 
Elekta Monaco® eMC algorithm to accurately predict 𝐷𝑤 in simple scenarios involving a 
homogeneous plastic water phantom. Chapter 4 builds further on the Elekta Monaco® eMC algorithm 
validation through dosimetric studies involving the measurement of 𝐷𝑚 in tissue equivalent slab 
phantoms. These chapters also outline the dosimetry calculation system used to obtain accurate 
absorbed dose measurements in plastic phantoms in terms of both 𝐷𝑤  and 𝐷𝑚. 
Chapter 5 addresses research question 2 through a statistical analysis of acute toxicity data for skin 
cancer patients treated with electron beams at MNCCI. It involves a cohort study to determine if there 
is a statistically significant difference in patient acute skin toxicity due to the change in clinical 




2 Literature review 
This chapter explores the literature in two key areas: electron dose calculation algorithms and acute 
toxicity. Electron dose calculation algorithms are explained from their rudimentary beginnings to the 
advanced techniques used in modern-day radiotherapy departments. A particular focus is on Monte 
Carlo techniques, with the Elekta Monaco® eMC algorithm explained in depth. The use of 𝐷𝑤 versus 
𝐷𝑚 in Monte Carlo treatment planning is also discussed. The radiobiological basis of acute toxicity, 
along with various acute toxicity classification schemes are outlined. A brief summary of published 
acute toxicity studies is provided, highlighting a gap in the current literature. This gap framed the 
basis for research question 2.     
2.1 Electron dose calculation algorithms  
2.1.1 A historical perspective 
Historically, patient dose calculations for electron beams have been carried out using broad-beam 
methods and more recently using the pencil-beam approach. Broad-beam dose calculation 
algorithms involved 1D ray-tracing with manual scaling of isodose curves in regions of inhomogeneity 
(Mayles, Nahum & Rosenwald 2007). This simplistic methodology was problematic due to its 
limitations in accurately modelling irregular fields and inhomogeneities. These limitations are 
particularly pronounced for electron beams due to dose in the build-up region at the patient surface 




Pencil-beam algorithms provided a significant advance, allowing for more sophisticated models to be 
produced. Pencil-beam models use the more realistic concept of a beam consisting of a large number 
of individual beamlets called “pencils”, where individual contributions from the pencils are integrated 
to obtain a dose distribution within the patient.  
To date, the Fermi-Eyges-Hogstrom pencil-beam model (Hogstrom, Mills & Almond 1981) has played 
a large role in commercial electron beam treatment planning systems. This pencil-beam approach 
has allowed modelling of irregular shaped fields due to its ability to sum doses over the shape of the 
collimator. In addition, it has partially been able to account for dose perturbations caused by tissue 
inhomogeneities.  
However, pencil-beam models also have some major limitations: most notably the central ray 
approximation where only those inhomogeneities on the central axis of each pencil are taken into 
account, resulting in a reduction in the contribution from lateral scatter. This limitation is highlighted 
by multiple studies that show poor agreement between experimental and modelled data in areas of 
large density contrast, such as the lung and the head and neck (Boyd, Hogstrom & Starkschall 2001; 
Ding et al. 2005; Ma et al. 1999). 
2.1.2 Monte Carlo methods 
More recently, Monte Carlo methods are being increasingly used for their improved calculation 
accuracy, particularly in inhomogeneous tissue, as compared with analytic dose algorithms. Monte 
Carlo methods are now widely regarded as the gold standard for radiotherapy treatment planning 




Monte Carlo-based dose calculation engines rely on a probability distribution function of the 
fundamental interaction processes of both neutral and charged particles in order to simulate individual 
particle transport histories. The probability distribution functions are sampled using a random number 
generator, creating a large number of solutions – as the number of samples increases to infinity, the 
variance reduces and the system converges to a solution with an acceptable statistical uncertainty.  
In clinical practice, this means a large number of particle histories may need to be computed in order 
for the Monte Carlo algorithm to determine an optimal solution (millions of histories may be required 
for complex calculations). This results in significant computation time, which is the main disadvantage 
of the Monte Carlo method. However, as computing power has increased, calculation time has 
subsequently decreased. Additionally, the use of phase-space and virtual source modelling has 
reduced the complexity of Monte Carlo calculations within the linac head. These developments have 
further reduced computation time, resulting in codes that are practical to use in a clinical environment.  
In terms of photon beam treatment planning, there has been an extensive body of work quantifying 
the accuracy of Monte Carlo calculated dose distributions. In general, they have been shown to be 
in excellent agreement with experimentally determined values (Ma et al. 1999; Paelinck et al. 2005). 
While collapsed cone convolution is arguably still the mainstay of photon treatment planning, such 
studies have led to Monte Carlo-based dose engines becoming increasingly common in radiotherapy 
clinics around the world.  
For electron beams, Monte Carlo calculations are more complex due to the relatively large number 
of interactions that take place compared with those of photon beams. In order for electron modelling 
to be feasible, approximations in the calculations need to be made – the most common approach 




individual interactions along an electron track into steps. The cumulative energy loss and angular 
deviations are then calculated only once per step.  
Despite this increased complexity, Monte Carlo-based dose engines for electron beams are also now 
used in the clinical environment. Authors investigating the use of Monte Carlo methods for clinical 
electron beams have been able to show good agreement between calculated and experimentally 
measured relative dose distributions in a variety of heterogeneous phantoms (Aubry et al. 2011; 
Coleman et al. 2005; Cygler et al. 2004; Fragoso et al. 2008). However, very few studies to date have 
focused on the accuracy of Monte Carlo-derived MU calculations by comparing them with absolute 
dose measurements within inhomogeneous media. Fragoso et al. (2008) compared absorbed dose 
measurements using a pin-point ionisation chamber and film in two heterogeneous slab phantoms 
and an anthropomorphic phantom with calculated values from the Pinnacle Monte Carlo electron 
dose algorithm. While agreement was shown to be mostly within ± 3%, the phantom arrangements 
were limited in their scope and there was no investigation regarding the clinical impact of changing 
to Monte Carlo derived MU calculations. Therefore, a degree of uncertainty remains associated with 
Monte Carlo MU calculations for electron treatments, and scope exists for a more detailed study to 
validate their use within the clinical environment. 
2.1.3 Monitor units 
In order for a radiation beam to deliver a known absolute dose to a certain point, the monitor unit 
ionisation chamber within a linac is calibrated under a set of reference conditions. For electron 
beams, the reference conditions are typically 100 cm source to surface distance (SSD) for a 10 cm 
x 10 cm field at the depth of dose maximum, zmax, within a water phantom. Most commonly, monitor 
unit ionisation chambers are calibrated such that 100 MU is defined as 1 Gray (Gy) as measured 




However, clinical reality is never this straightforward due to the large range of conditions encountered 
in patient treatments. To overcome this, dose measurements are made relative to the reference 
situation allowing for doses to be calculated at other points and for the range of clinical conditions 
likely to be encountered. Factors that affect the dose delivered to the patient, and hence the number 
of MU that need to be delivered in order to achieve the prescribed dose, include the field size, the 
distance from the radiation source, the distance from the beam central axis, the composition of the 
patient and any accessories required (e.g. bolus, Cerrobend cut-outs).  
MU calculations are a critical part of treatment planning as they convert the prescribed absorbed 
dose to the patient to the required reading on the monitor unit ionisation chamber (i.e. the number of 
MU to be delivered by the linac). Modern day treatment planning systems are able to perform these 
calculations. However, more simplistic manual MU calculations may also be performed, and are often 
done as an independent check. In terms of electron treatments, MU calculations can also be 
performed using cut-out factor measurements in water or plastic water phantoms.  
Due to the limitations and simplicity of conventional pencil-beam algorithms, standard practice has 
been to use the more accurate, water-based measurements to calculate MU for electron treatments, 
rather than to rely on calculated values as determined by the TPS. This approach was standard 
practice at MNCCI up until 2018, whereby a cut-out factor measurement was carried out in a plastic 
water phantom for each customised cut-out, with a manual calculation subsequently performed. In 
this case, the number of MU delivered to the patient can be calculated using: 




 × # × 𝑂𝐹 × 𝑇𝑥 𝑖𝑠𝑜𝑑𝑜𝑠𝑒 (%) × 0.01 




where 𝑇𝑥 is the prescription dose, 
𝐷𝑜𝑠𝑒
𝑀𝑈
 is the dose per MU measured under reference conditions for 
the specific beam energy, # is the number of fractions, 𝑂𝐹 is the measured cut-out factor of the 
patient specific applicator insert and 𝑇𝑥 𝑖𝑠𝑜𝑑𝑜𝑠𝑒 is the isodose to which the dose is prescribed. 
Monte Carlo-based treatment planning systems are capable of calculating patient dose for highly 
realistic clinical situations taking into account the irregular surface and complex tissue 
inhomogeneities of each individual patient. Therefore, Monte Carlo-derived MU calculations should 
be more accurate. However, differences between electron Monte Carlo-derived MU calculations and 
water-based measurements of up to 10% have been observed, particularly for head and neck 
tumours where large density differences exist for cortical bone and air cavities, combined with 
significant patient surface irregularity (Cygler et al. 2005). In this specific case, the Monte Carlo 
calculations required more MU to deliver the required dose. If it is assumed that the Monte Carlo 
approach is more accurate, then the logical follow-on is that water-derived MU values would have 
led to an under-dosing of this particular site.  
The work carried out by Cygler et al. (2005) led their team to change clinical practice, adopting the 
Monte Carlo-based MU, resulting in sometimes significant changes (8-10%) to the absorbed dose 
delivered to the patient. Given that published evidence suggests that dose differences on the order 
of 7% may be clinically detectable (Dutreix 1984), the obvious question is what clinical impact do 
these dose differences have on the patient in terms of both normal tissue toxicity and tumour control? 
2.1.4 Dose to water versus dose to medium  
A major implication of Monte Carlo-based treatment planning systems is that doses are calculated 




dose algorithms take into account particle transport interactions specific to the molecular structure of 
the material in which they occur. 
In contrast, conventional photon and electron beam dose calculation algorithms have computed and 
reported doses as though they were deposited in water i.e. 𝐷𝑤. Historically, 𝐷𝑤-based algorithms 
have been deemed reasonable as water makes up the majority of the human body. Indeed 
international dosimetry protocols such as The American Association of Physicists in Medicine 
(AAPM) TG-51 (Almond et al. 1999) and The International Atomic Energy Agency (IAEA) TRS-398 
(Andreo et al. 2006) are all based on 𝐷𝑤, thus providing a direct link between dose calculations and 
a traceable calibration.  
Using energy dependant stopping power ratios, it is possible to convert 𝐷𝑤 to 𝐷𝑚  (and vice versa) 
using a procedure based on the Bragg-Gray cavity theory. If the detector used to measure dose is 
small compared to the range of electrons traversing the detector, and if the introduction of the detector 
into the medium of interest does not disturb the electron fluence, the following Bragg-Gray relation 
























Spencer-Attix electron mass stopping power for the specific medium, 𝑚. 
In most cases, due to the bulk of human soft tissue being almost equivalent to water, differences 
between 𝐷𝑚 and 𝐷𝑤  are unlikely to be significant. However, studies that have compared Monte 
Carlo-derived 𝐷𝑚  values with converted 𝐷𝑤  values in photon beam intensity modulated radiation 




histograms (DVHs) when examining sites with high density contrasts. Dogan, Siebers & Keall (2006) 
have shown DVH differences of up to 5.8% for head and neck treatment sites and 8% in prostate 
cases (where hard bone femoral heads are present). Such significant variation between the 𝐷𝑚 and 
converted 𝐷𝑤  values has led many to ask whether doses should be prescribed and reported in terms 
of 𝐷𝑚 or 𝐷𝑤 (Liu & Keall 2002; Ma & Li 2011).  
While there is a gradual shift to Monte Carlo-based treatment planning systems and hence 𝐷𝑚  based 
data, the huge wealth of historical radiotherapy data, including toxicity information and clinical 
outcome, is based on 𝐷𝑤  prescriptions. Therefore, it is important that any shift in clinical practice 
toward a 𝐷𝑚-based system be built on a sound understanding of the dosimetric and clinical 
differences between 𝐷𝑚  and 𝐷𝑤 . 
2.1.5 The Elekta Monaco® eMC algorithm  
The Elekta Monaco® eMC algorithm consists of two main components: an electron beam phase 
space engine and a dose calculation engine.  
The phase space engine is a model of the transport of the electron beam through the linac treatment 
head, designed to reduce calculation times. The phase space is divided into two key parts as shown 
in Figure 2.1. The source phase space starts upstream of the uppermost collimating component. It is 
propagated through the treatment head to the exit phase space plane, located at the lowermost 
collimating element i.e. immediately in front of the applicator insert. This interface defines the start of 
the dose calculation engine (Elekta 2014).  
For fixed collimator set-ups, the in-patient dose calculation starts by sampling from a parameterised 




the treatment head for each dose calculation. For example, in the case of fixed applicators (with pre-
set jaw positions) as are used at MNCCI, the source phase space is pre-propagated to the exit phase 
space plane. For non-fixed collimation set ups, the dose calculation samples directly from the source 
phase space.  
 
Figure 2.1: Electron beam transport from the source phase space to the exit phase space plane 
(reproduced from Elekta (2014)). 
Modelling of radiation transport through the patient and calculating the dose deposition is performed 
in the dose calculation engine, which uses the VMC++ Monte Carlo algorithm (Kawrakow & Fippel 
2000). This algorithm is considered a Class II algorithm, a classification used to describe the way it 
samples electron energy losses. In Class II algorithms, the generation of secondary electrons directly 
affects the energy loss and angular deviations of the primary electrons, providing a simulation that is 




the Condensed History approximation (Berger 1963) and a technique called Simultaneous Transport 
of Particle Steps (STOPS) whereby particles of the same energy form a “particle set” and are 
transported simultaneously.  
In the Elekta Monaco® eMC algorithm, the patient anatomy is represented by a 3D matrix of relative 
electron density (RED) data. The properties in each voxel within this matrix are derived from CT 
numbers (measured in Hounsfield Units) obtained from a series of CT sectional images of the patient 
or phantom. A user-defined CT-to-RED conversion table is then used to determine the RED within 
each voxel. The resulting 3D RED matrix is passed to the dose calculation engine.  
The dose calculation engine assigns a tissue type or element to each voxel, based on its RED and 
the 12 individual composition bins as shown in Table 2.1. It is not clear from available Elekta 
documentation how interpolation of tissue type as a function of RED is performed. Tissue types are 
defined using the elemental compositions as defined in The International Commission on Radiation 
Units and Measurements (ICRU) Report 44 (White et al. 1989) and The International Commission on 
Radiological Protection (ICRP) Report 23 (Snyder et al. 1975). For cases where the RED is greater 












Lung (ICRU 44) 0.50 
Adipose (ICRU 44) 0.95 
Muscle (ICRU 44) 1.04 
Cartilage (ICRP) 1.08 
2/3 Cartilage, 1/3 Bone 1.29 
1/3 Cartilage, 2/3 Bone 1.52 
Bone (ICRP 23) 1.95 
½ Bone, ½ Aluminium 2.15 
Aluminium 2.46 
Iron > 2.46 
Water 1.00 
Table 2.1: Compositions used by the Elekta Monaco® eMC dose calculation engine based on the 
RED of individual voxels (Elekta 2014). 
The Elekta Monaco® eMC dose calculation engine has three dose calculation options available, which 
are described below. 
• 𝐷𝑚: the transport of particles through the patient is modelled using interaction cross sections 
of the medium. The absorbed dose in each voxel is calculated using the stopping power of 
the medium in that voxel. 
• 𝐷𝑤: the transport of particles through the patient is still carried out using interaction cross 
sections for the medium. However, the Elekta Monaco® eMC algorithm scores the dose 




• Dose forced to water (DFw): in this case, the entire patient is represented as pure water (i.e. 
the RED is equal to 1.00). The Elekta Monaco® eMC algorithm models the transport of 
particles through the patient and scores the dose deposition in terms of water. Therefore, 
both the interaction cross sections and the stopping power are for water.  
The dose calculation options used in this research project are primarily DFw (in Chapter 3) and 𝐷𝑚 
(in Chapter 4 and Chapter 5). 
2.2 Acute toxicity 
To date, little work has been carried out to quantify the clinical effect on patients from changing to a 
Monte Carlo 𝐷𝑚-based treatment planning approach in the case of clinical electron beams. Acute 
toxicity is one radiobiological measure that could be used to judge the effect of such a change. Given 
the observation at MNCCI that more MU, on average, were delivered in patient treatments when 
using the calculated 𝐷𝑚-based MU, acute toxicity is a logical outcome to assess. 
In radiotherapy, toxicity refers to any side effects that occur as a result of radiation treatment. 
Generally, side effects that occur within 90 days of irradiation are considered acute, while those that 
occur after 90 days are referred to as late. Acute toxicity results from the death of a large number of 
cells and may occur within a few days or weeks after irradiation. For these cells, damage is quickly 
repaired because of the rapid proliferation of stem cells and so is usually completely reversible. Acute 
effects occur mainly in tissue with rapid cell turnover such as the skin, gastrointestinal epithelium and 
the hematopoietic system.  
Standardised classification schemes to quantify acute toxicity have been devised, which take into 




the grading system to be used. Examples of classification schemes include RTOG/EORTC (Cox, 
Stetz & Pajak 1995) and CTCAE (U.S Department of Health and Human Services 2009). These 
systems are used on a regular basis by treatment staff within a radiotherapy department to assess 
the severity of patient acute toxicity during and after treatment. These assessments are then stored 
within the patient record.  
Acute skin toxicity is particularly common in radiotherapy treatment – it can range from low-level 
symptoms such as dull erythema and dry desquamation to severe disorders including ulceration, 
haemorrhage and necrosis. In the case of these severe skin reactions (i.e. Grade 3 and Grade 4), 
permanent skin changes may result. Furthermore, associated pain and discomfort may lead to 
temporary or permanent cessation of radiation treatment. Therefore, it is vitally important that acute 
toxicity is minimised, assessed regularly and managed proactively by treatment staff.  
Studies in this field are often used to identify predictive factors (clinical or dosimetric) of radiation-
induced toxicity for a particular treatment type. For example, a study investigating radiation-induced 
skin toxicity in breast cancer patients found that dose inhomogeneities greater than 107% of the 
prescribed dose were the most important predictor of Grade 2 and Grade 3 acute skin reactions 
(Tortorelli et al. 2013).  
Alternatively, studies may be performed that compare the severity of acute toxicity across two cohorts 
of patients who underwent different treatment methodologies. For example, an acute toxicity cohort 
comparison was performed for 3D conformal proton therapy versus IMRT for head and neck cancer 
patients (McDonald et al. 2016). The study found that proton therapy was associated with reduced 
rates of gastrostomy tube dependence and pain. In another example, a cohort study compared the 
severity of acute skin toxicity in breast cancer patients: one cohort was treated with image guided 




portal imaging device (EPID). The study found the severity of acute radiation dermatitis was 
significantly lower for patients in the IGRT cohort (Lin et al. 2018).   
This literature review identified no studies that investigated differences in acute skin toxicity for 
electron patients treated with 𝐷𝑤-based MU compared with patients treated with Monte Carlo-derived 
𝐷𝑚-based MU. Given the differences reported between Monte Carlo-derived MU calculations and 
MU calculations based on water measurements, particularly in areas containing significant tissue 
inhomogeneity, a clinically observable difference in skin reaction between the two methodologies is 
plausible. This gap in the literature provides a unique opportunity to better assess the clinical effect 




3 Validation of dose to water in the Elekta Monaco® eMC 
algorithm in a homogeneous plastic water phantom 
To answer research question 1, a two-step approach is required. This chapter describes the first step, 
whereby a simple scenario is tested in the Elekta Monaco® eMC algorithm in terms of 𝐷𝑤. 
3.1 Introduction 
A comparison was performed between dose measured with an ionisation chamber and dose 
calculated by the Elekta Monaco® eMC algorithm in a homogeneous plastic water phantom. The 
purpose of this comparison was to validate the ability of the Elekta Monaco® eMC algorithm to 
accurately predict the 𝐷𝑤 in a simple scenario, thereby building confidence so that studies in more 
complex scenarios could be addressed (these are described in Chapter 4).  
In addition, these measurements allowed a dosimetry calculation system to be developed for a 
cylindrical ionisation chamber, so that absorbed dose to water traceable to The Australian Radiation 
Protection and Nuclear Safety Agency (ARPANSA) could be accurately determined from ionisation 
measurements in electron beams. If the results validated that the cylindrical ionisation chamber was 
able to accurately measure the 𝐷𝑤 in electron beams, it was thought that the dosimetry calculation 




3.2 Materials and methods 
3.2.1 Radiation detector  
The radiation detector used for all measurements was an IBA CC04 cylindrical ionisation chamber 
(serial number 14571). This ionisation chamber has a relatively small cavity volume of 0.04 cm3, with 
a cavity length and radius of 3.6 mm and 2 mm respectively.  
Ideally, a plane parallel ionisation chamber would have been used. Plane parallel chambers are 
considered the gold standard in electron beam dosimetry due to their physical characteristics (e.g. 
disc-type shape and guard rings, which minimise scatter perturbation effects) that make them ideal 
in electron beams. However, the CC04 cylindrical ionisation chamber was selected based on its 
ability to fit within the various phantoms used in the intended full scope of this research project. 
To ensure that the CC04 cylindrical ionisation chamber could accurately measure dose in electron 
beams, percentage depth dose (PDD) measurements using the CC04 cylindrical ionisation chamber 
were compared with those using a PTW Roos® plane parallel ionisation chamber (sensitive volume: 
0.35 cm3, sensitive volume radius: 7.8 mm, sensitive volume depth: 2 mm). Percentage depth 
ionisation (PDI) scans (10 cm x 10 cm applicator, 100 cm SSD, gantry and collimator at 0°) for each 
electron beam energy were performed in a full-scatter water tank (IBA Blue Phantom) using the CC04 
ionisation chamber and Roos® chamber as the field detector and a CC13 ionisation chamber as the 
reference detector. Conversion to PDD was carried out within IBA OmniPro software according to 
the IAEA TRS-398 dosimetry protocol.  
The CC04 ionisation chamber was cross calibrated for use in electron beams according to IAEA TRS-




cross calibration was performed using a cross calibration beam quality, 𝑄𝑐𝑟𝑜𝑠𝑠, of 15 MeV (the 
highest electron energy available in the local department). During the cross calibration, values for the 
polarity correction factor, 𝑘𝑝𝑜𝑙, and the recombination correction factor, 𝑘𝑠, were determined. To 
validate the cross calibration factor obtained, an absorbed dose determination according to the IAEA 
TRS-398 protocol was carried out for all electron beams using the CC04 ionisation chamber, followed 
by the same measurements using a calibrated Roos® plane parallel chamber. 
3.2.2 Homogeneous plastic water phantom 
The phantom used for all measurements was the IBA IMRT phantom, which is shown in Figure 3.1. 
This phantom is approximately torso shaped, is composed of RW3 plastic material (composition: 98% 
polystyrol + 2% Ti02; nominal density: 1.045 g/cm3) and has a modular design allowing ionisation 
chamber placement at various depths within the phantom geometry. 
 
 
Figure 3.1: A transverse slice through the IBA IMRT phantom used for depth-dose measurements 
with the CC04 cylindrical ionisation chamber. The particular slice shown is positioned at the centre 





The electrometer used for all measurements was a Scandatronix Wellhofer Dose 1 (serial number 
16717) with a bias voltage of +300 V applied. A 60-second background reading was taken and 
subtracted from all subsequent measurements. The electrometer correction factor, 𝑘𝑒𝑙𝑒𝑐, used for 
absorbed dose determination was obtained from the relevant ARPANSA calibration certificate. 
3.2.4 Electron beam energies 
Electron beam energies available for use in the local department are 6 MeV, 9 MeV, 12 MeV and 15 
MeV – all electron beams were investigated as part of this research project. 
3.2.5 Creation of treatment plans  
The IMRT phantom was scanned using a 64-slice Siemens SOMATOM Confidence CT scanner. 
Data was exported to the Monaco® TPS where a series of electron plans were created and dose 
calculations performed. The steps undertaken to obtain the treatment plans in the Elekta Monaco® 
eMC algorithm are outlined below. 
• The phantom was placed on the CT couch and scanned using one of the standard clinical 
protocols used in the department. 
• The CT dataset was imported into the Monaco® TPS via DICOM-RT. 
• The external boundary of the CT dataset was contoured. 
• Electron plans were created for each energy, using a 10 cm x 10 cm applicator, at 100 cm 




• Dose calculations were performed in the Elekta Monaco® eMC algorithm by delivering 100 
MU, using the DFw dose deposition option. To determine the optimal calculation settings, 
calculations were performed using two scenarios: 1,000,000 histories with a grid cell size of 
0.1 cm (named “detailed” plans), and 750,000 histories with a grid cell size of 0.2 cm (named 
“standard” plans).  
• Sagittal dose planes from each of the dose calculations were exported from the Monaco® 
TPS and subsequently imported into Microsoft Excel as text files.  
• Point doses were extracted from the Monaco® TPS dose plane data in Microsoft Excel at 
the ionisation chamber measurement points that would be used within the IMRT phantom.  
3.2.6 Phantom set-up and measurements 
The phantom was set up to the isocentre on the treatment couch, at 100 cm SSD and with the gantry 
and collimator set to 0°. Charge measurements were taken with the ionisation chamber at various 
depths within the IMRT phantom. The measurement depths were selected to obtain adequate data 
coverage over the area from approximately R100 to R50 and, therefore, were dependent on the 
electron energy (where R100 is the depth in water at which the absorbed dose is maximum and R50 is 
the depth in water at which the absorbed dose is 50% of its maximum value). The effective point of 
measurement of the ionisation chamber was accounted for when placing the chamber at each 
measurement location. A minimum of 10 cm of backscatter material and 5 cm of lateral side-scatter 
material within the phantom was present around the chamber for all measurements.  
Three 100 MU exposures were delivered at each measurement depth and for each energy. For each 




Temperature and pressure readings were taken at regular intervals during data collection in order to 
calculate the temperature and pressure correction factor, 𝑘𝑡𝑝, necessary for absorbed dose 
determination.  
3.2.7 Dose calculation formalism (𝑫𝒘) 
The absorbed dose to water, 𝐷𝑤,𝑄, at the user beam quality 𝑄 was determined from ionisation 
measurements according to the IAEA TRS-398 protocol as follows: 
𝐷𝑤,𝑄 = 𝑀𝑄 𝑁𝐷,𝑤,𝑄𝑐𝑟𝑜𝑠𝑠 𝑘𝑄,𝑄𝑐𝑟𝑜𝑠𝑠       [3.1] 
where 𝑁𝐷,𝑤,𝑄𝑐𝑟𝑜𝑠𝑠 is the chamber calibration factor in terms of absorbed dose to water at the cross 
calibration beam quality, 𝑘𝑄,𝑄𝑐𝑟𝑜𝑠𝑠 is the beam quality correction factor to account for the difference 
between the response of the ionisation chamber in the user beam quality and the cross calibration 
beam quality and 𝑀𝑄 is the reading of the ionisation chamber at the user beam quality, corrected for 
influencing quantities as given by: 
𝑀𝑄 = 𝑀1 𝑘𝑡𝑝 𝑘𝑠 𝑘𝑝𝑜𝑙 𝑘𝑒𝑙𝑒𝑐        [3.2] 
According to IAEA TRS-398 Section 7.7 (“Measurements under non-reference conditions”), 
measured depth-ionisation readings must be converted to depth-dose by multiplying them by the 
water-to-air Spencer-Attix stopping power ratio, 𝑠𝑤,𝑎𝑖𝑟, for the electron beam quality specifier R50 at 
the depth of interest. Values for the stopping power ratios were obtained from IAEA TRS-398 Table 
7.V by interpolation between table entries. To obtain the stopping power ratio correction factor that 
was applied to the ionisation readings, the stopping power ratio at the depth of interest was 
normalised to the stopping power ratio at the reference depth, 𝑧𝑟𝑒𝑓. The rationale for this step is 




From equation 3.1, at 𝑧𝑟𝑒𝑓: 




 (𝑤𝑎𝑖𝑟)𝑄 𝑧𝑟𝑒𝑓   𝑝𝑄 𝑧𝑟𝑒𝑓
(𝑠𝑤,𝑎𝑖𝑟)𝑄𝑐𝑟𝑜𝑠𝑠 
 (𝑤𝑎𝑖𝑟)𝑄𝑐𝑟𝑜𝑠𝑠  𝑝𝑄𝑐𝑟𝑜𝑠𝑠
      [3.4] 
where 𝑤𝑎𝑖𝑟 is the mean energy expended in air per ion pair formed at the particular beam quality 𝑄 
or 𝑄𝑐𝑟𝑜𝑠𝑠 and 𝑝 is the overall perturbation factor for the ionisation chamber at the particular beam 
quality 𝑄 or 𝑄𝑐𝑟𝑜𝑠𝑠. 
At any measurement depth, 𝑧: 








        [3.6] 
From equation 3.6: 
𝑘𝑄𝑧𝑟𝑒𝑓
𝑘𝑄𝑐𝑟𝑜𝑠𝑠








 (𝑤𝑎𝑖𝑟)𝑄 𝑧𝑟𝑒𝑓   𝑝𝑄 𝑧𝑟𝑒𝑓









 (𝑤𝑎𝑖𝑟)𝑄 𝑧𝑟𝑒𝑓  𝑝𝑄 𝑧𝑟𝑒𝑓
) × 𝑘𝑄,𝑄𝑐𝑟𝑜𝑠𝑠     [3.9] 
Substituting equation 3.9 and assuming 𝑤𝑎𝑖𝑟 and 𝑝𝑄 are constants, equation 3.5 becomes: 
𝐷𝑤,𝑄(𝑧) = 𝑀𝑄 (𝑧) 𝑁𝐷,𝑤,𝑄𝑐𝑟𝑜𝑠𝑠 𝑘𝑄,𝑄𝑐𝑟𝑜𝑠𝑠
(𝑠𝑤,𝑎𝑖𝑟)𝑄𝑧
(𝑠𝑤,𝑎𝑖𝑟)𝑄 𝑧𝑟𝑒𝑓
     [3.10] 
3.2.8 Electron dosimetry considerations in plastic phantoms 
When depth-dose measurements are carried out in plastic, the depths must be scaled to give the 
equivalent depths in water (i.e. depth-scaling), while the dosimeter readings must be scaled to give 
the equivalent reading in water (i.e. fluence-scaling). Both depth-scaling and fluence-scaling of all 
depth-dose measurements were carried out using the methodology given in Section 7.8 of IAEA TRS-
398. The methodology is summarised here for reference.  
Each measurement depth in plastic, 𝑧𝑝𝑙, was scaled to give the equivalent depth in water, 𝑧𝑤, using: 
𝑧𝑤 = 𝑧𝑝𝑙 𝑐𝑝𝑙          [3.11] 
where 𝑐𝑝𝑙 is known as the depth-scaling factor, and both 𝑧𝑤 and 𝑧𝑝𝑙 are expressed in units of g cm2.  
The depth in plastic, 𝑧𝑝𝑙, was determined by multiplying the physical measurement depth (in cm) by 
the physical density of the plastic, 𝜌𝑝𝑙. As per the recommendation in IAEA TRS-398, the physical 
density was measured for the specific batch of RW3 plastic in the IMRT phantom. Measurement of 
the plastic dimensions was made using a micrometer while the mass was measured using high 




Values of 𝑐𝑝𝑙 for certain plastic types are provided in Table 7.VI of IAEA TRS-398 and are reproduced 
in Table 3.1. As RW3 plastic is not included in this table, it was necessary to obtain a customised 
depth-scaling factor. 
 
Plastic phantom 𝒄𝒑𝒍  𝒉𝒑𝒍  𝝆𝒑𝒍 (g/cm3) 
Solid water® (WT1) 0.949 1.011 1.020 
Solid water® (RMI-457) 0.949 1.008 1.030 
Plastic water 0.982 0.998 1.013 
Virtual water 0.946 Not available 1.030 
PMMA 0.941 1.009 1.190 
Clear polystyrene 0.922 1.026 1.060 
White polystyrene 0.922 1.019 1.060 
A-150 0.948 Not available 1.127 
Table 3.1: Values of the depth-scaling factor, fluence-scaling factor (ℎ𝑝𝑙) and physical density for 
various plastic types, reproduced from Table 7.VI of IAEA TRS-398 (Andreo et al. 2006). 
To determine the customised depth-scaling factor, depth-dose measurements were carried out using 
the CC04 ionisation chamber in a water tank, followed by the same measurements in the IMRT 
phantom. For the water tank measurements, PDI scans (10 cm x 10 cm applicator, 100 cm SSD, 
gantry and collimator at 0°) for each electron beam energy were obtained using the CC04 ionisation 
chamber as the field detector and a CC13 ionisation chamber as the reference detector. Conversion 
to PDD was carried out within IBA OmniPro software according to the IAEA TRS-398 protocol.  
PDI measurements (10 cm x 10 cm applicator, 100 cm SSD, gantry and collimator at 0°) for each 
electron energy were then performed in the IMRT phantom using the CC04 ionisation chamber. 
100 MU were delivered, with three charge readings taken at each depth and for each energy, with 
the result averaged. Conversion to PDD was carried out by manually applying the appropriate 




An overall depth-scaling factor, referred to here as “ODSF”, was determined by applying various 
factors to the IMRT phantom measurement depths until the root mean square error between the 
PDDs measured in water and the PDDs measured in the IMRT phantom was minimised. From 
determination of the ODSF value and the measured physical density of the plastic, the depth-scaling 
factor, 𝑐𝑝𝑙, could be calculated using: 
𝑐𝑝𝑙 =  
𝑂𝐷𝑆𝐹
 𝜌𝑝𝑙
          [3.12] 
In addition to depth-scaling, the dosimeter reading at each depth in plastic, 𝑀𝑄,𝑝𝑙, must also be 
scaled by the fluence-scaling factor, ℎ𝑝𝑙 , to obtain the equivalent reading in water, 𝑀𝑄, using: 
𝑀𝑄 = 𝑀𝑄,𝑝𝑙 ℎ𝑝𝑙         [3.13] 
As per the methodology given in IAEA TRS-398, for depths beyond the reference depth in plastic, 
𝑧𝑟𝑒𝑓,𝑝𝑙, the determined value of ℎ𝑝𝑙  at 𝑧𝑟𝑒𝑓,𝑝𝑙 is used. For shallower depths, this value of ℎ𝑝𝑙  is 
decreased linearly to a value of unity at zero depth.  
Similar to the depth-scaling factor, no ℎ𝑝𝑙  value for RW3 plastic is available in IAEA TRS-398. The 
ℎ𝑝𝑙  value used for fluence-scaling of charge measurements was obtained from Table 7.VI of IAEA 
TRS-398 (reproduced in Table 3.1) for the plastic type that provided the closest match of the 𝑐𝑝𝑙 and 
𝜌𝑝𝑙 values determined for the IMRT phantom. The uncertainty associated with this assumption for 





3.3.1 Validation of the CC04 ionisation chamber for use in electron beams  
PDD measurements performed in water using the CC04 ionisation chamber and the Roos® plane 
parallel chamber for all electron energies are shown in Figure 3.2. At the depths of clinical significance 
(i.e. from approximately R100 to R80 where R80 is the depth in water at which the absorbed dose is 
80% of its maximum value), the maximum discrepancy between the measurements performed with 
the CC04 ionisation chamber and the Roos® plane parallel chamber was ± 1.5%. This level of 
agreement was deemed to be acceptable and validates that the CC04 ionisation chamber is an 
acceptable detector for the accurate measurement of percent depth dose in the electron beams under 
investigation in this research project. 
 
Figure 3.2: PDD measurements using the Roos® plane parallel chamber and the CC04 ionisation 
chamber in water for all electron beam energies. The Elekta Monaco® eMC DFw calculated data are 




The absorbed dose determination results from both the CC04 ionisation chamber and the Roos® 
plane parallel chamber were within 1% of nominal (i.e. 1 cGy/MU) and the CC04 ionisation chamber 
results were within 1% of the Roos® plane parallel chamber results. This level of agreement was 
deemed to be acceptable and validates that the CC04 ionisation chamber is an acceptable detector 
for the accurate measurement of absorbed dose in the electron beams under investigation in this 
research project.  
3.3.2 Optimal dose calculation parameters and export format 
An analysis was performed to determine which data export format (i.e. interest point dose or dose 
plane) and which Elekta Monaco® eMC calculation parameters (i.e. standard or detailed) provided 
the best level of agreement between the calculated and measured datasets. The exported dose plane 
data (with point doses subsequently extracted from it) and the detailed calculations provided the best 
agreement with the measured data. This analysis was performed for 6 MeV and 15 MeV beams only, 
but it is reasonable to assume that similar results would be obtained for the 9 MeV and 12 MeV 
beams. Therefore, all Elekta Monaco® eMC data used in this research project are calculated in 
detailed mode and extracted from exported dose planes.  
3.3.3 Determination of the physical density, depth-scaling and fluence-scaling factors 
The physical density of the IMRT phantom plastic, 𝜌𝑝𝑙, was measured as 1.043 g/cm3 ± 0.4%, which 
agrees (within the experimental uncertainty) with the manufacturer stated value of 1.045 g/cm3. 
The ODSF value that minimised the root mean square error between PDD data measured in water 
and PDD data measured in the IMRT phantom was 0.98 ± 1% for all electron energies. Figure 3.3 




for all energies, with the measurement depths in the plastic multiplied by the optimal ODSF value of 
0.98.  
Using the measured 𝜌𝑝𝑙 and the ODSF value obtained, the value for the depth-scaling factor, 𝑐𝑝𝑙, 
was determined to be 0.94 ± 1.1% using equation 3.12. 
 
Figure 3.3: PDD measurements using the CC04 ionisation chamber in water and in the IMRT 
phantom for all electron energies. The customised ODSF of 0.98 has been applied to the physical 
measurement depths in the IMRT phantom. 
As Table 3.1 shows, the plastic type that provided the closest match to both the 𝑐𝑝𝑙 and 𝜌𝑝𝑙 values 
obtained for RW3 plastic was “Solid water® (RMI-457)”. Therefore, the ℎ𝑝𝑙  value used in subsequent 






Table 3.2 summarises the physical density and scaling factors used in subsequent dose calculations 
using the IMRT phantom. 
 
Plastic phantom 𝒄𝒑𝒍  𝒉𝒑𝒍  𝝆𝒑𝒍 (g/cm3) 
IBA IMRT (RW3 plastic) 0.94 ± 1.1% 1.008 ± 0.4% 1 1.043 ± 0.4% 
Table 3.2: Values of the depth-scaling factor, fluence-scaling factor and physical density for the IBA 
IMRT phantom (RW3 plastic). 1The fluence-scaling factor was taken from IAEA TRS-398 as a “best 
match” to Solid water® (RMI-457). 
3.3.4 Comparison between Elekta Monaco® eMC dose calculations and measured 𝑫𝒘 in the 
homogeneous plastic water phantom 
The final results comparing the level of agreement between the Elekta Monaco® eMC DFw dose 
calculations and the depth-dose data measured in the IMRT phantom are shown in Figure 3.4, while 
Table 3.3 quantifies the differences observed. The physical measurement depths in the IMRT 







Figure 3.4: Comparisons of Elekta Monaco® eMC DFw dose calculations and the measured 𝐷𝑤 
(using the CC04 ionisation chamber) in the IMRT phantom for all electron beams. The customised 
ODSF of 0.98 has been applied to the physical measurement depths in the IMRT phantom.  
 
Table 3.3: Differences between the Elekta Monaco® eMC DFw dose calculations and the measured 
𝐷𝑤 in the IMRT phantom for all electron beams (normalised to the maximum DFw calculated dose). 
Difference values exceeding 3% are highlighted in red.  
Differences between the Elekta Monaco® eMC DFw dose calculations and the measured 𝐷𝑤 data 
are within ± 3% for the 9 MeV, 12 MeV and 15 MeV beams, while larger discrepancies of up to 4.1% 

























1 0.9% 1 -0.6% 1 1.6% 2 2.5%
1.3 1.4% 1.5 0.2% 2 -1.7% 2.6 1.9%
1.5 1.9% 2 -0.7% 3 -1.2% 3.5 1.2%
1.8 2.9% 2.5 0.5% 4 -1.7% 4.5 -1.8%
2 4.1% 3 1.0% 5 0.7% 5 -1.7%
2.5 2.1% 3.5 2.0% 6 -1.0%
4 1.9%





The comparison of 𝐷𝑤 measured in a simple, homogeneous plastic water phantom with the Elekta 
Monaco® eMC DFw calculated data is within ± 3% for the 9 MeV, 12 MeV and 15 MeV electron 
beams. The relative standard uncertainty in the measured 𝐷𝑤  data is at least 2.4%. This estimate is 
based on uncertainties quoted in IAEA TRS-398 at the reference depth in water for a cylindrical 
ionisation chamber used in electron beams (which has been calibrated in 60Co). It also accounts for 
the additional uncertainty due to the cross calibration of the secondary standard NE 2571 ionisation 
chamber with the CC04 ionisation chamber and subsequent use of the CC04 ionisation chamber for 
depth-dose measurements. The uncertainty is likely to be higher at depths away from the reference 
depth, and due to the measurements being performed in plastic. The uncertainty in the Elekta 
Monaco® eMC dose calculations could not be quantified due to the random number generator seed 
remaining the same for repeated calculations.  
The AAPM recommend a tolerance level of 3%/3 mm for basic TPS validation in the case of electron 
dose calculation algorithms (Smilowitz et al. 2015). Based on these recommendations, the dose 
comparison results obtained for the 9 MeV, 12 MeV and 15 MeV electron beams validate that the 
Elekta Monaco® eMC algorithm is able to accurately predict the dose in a simple scenario for these 
beam energies.  
However, there is a larger discrepancy (up to 4.1%) observed for the 6 MeV data. It is likely that this 
discrepancy is affected, at least in part, by the steep gradient of the 6 MeV PDD curve (i.e. 6.9%/mm 
in the region of approximately R90 to R40, where R40 is the depth in water at which the absorbed 
dose is 40% of its maximum value). Any small errors in the measurement depth (e.g. due to 
inaccurate machining of the plastic water slabs within the IMRT phantom or increased air gaps 




measured data, leading to a greater discrepancy with the Elekta Monaco® eMC data. Given the error 
in the thickness of the plastic water slabs was 0.05 mm per slab (nominal thickness of 1 cm), at a 
physical depth of 2 cm, the combined error in the slab thickness would lead to a 0.7% difference in 
the PDD value. 
Additionally, 𝑘𝑄,𝑄𝑖𝑛𝑡 factors (i.e. beam quality correction factors that account for the difference 
between the response of the ionisation chamber in the user beam quality 𝑄 and an intermediate 
beam quality 𝑄𝑖𝑛𝑡) are not available in IAEA TRS-398 for cylindrical chambers in electron beams 
with a R50 less than 4 g cm2. In this case, 𝑘𝑄,𝑄𝑖𝑛𝑡 factors could only be obtained for the 12 MeV (R50 
= 4.72 cm) and 15 MeV (R50 = 6 cm) beams, while factors for the 6 MeV (R50 = 2.39 cm) and 9 MeV 
(R50 = 3.48 cm) beams have been extrapolated. Therefore, there is an increased level of uncertainty 
in the beam quality correction factors, 𝑘𝑄,𝑄𝑐𝑟𝑜𝑠𝑠, and the measured absorbed dose data for the 
6 MeV and 9 MeV beams. 
There is significant variation in perturbation factors with depth in electron beams when measured 
using a cylindrical ionisation chamber. IAEA TRS-398 states that perturbation factors for such 
chambers have only been determined close to the reference depth. For this reason, this protocol 
discourages the use of cylindrical ionisation chambers for measurements of depth-dose distributions 
in electron beams. Instead, well-guarded plane parallel chambers are recommended, as they exhibit 
minimal variation in the perturbation factor with depth. However, the results obtained in this research 
project show that the CC04 cylindrical ionisation chamber produces an acceptable level of agreement 
with a well-guarded Roos® plane parallel chamber for depth-dose measurements in all of the electron 
beams under investigation.  
IAEA TRS-398 states that the use of plastic phantoms is permitted in electron beams with beam 




in electron beams is strongly discouraged as large errors in the determination of absorbed dose can 
result. These errors are mainly due to the uncertainty related to the scaling factors applied. By using 
a customised depth-scaling factor, and measurement of the physical density of the specific plastic 
batch used in the IMRT phantom, uncertainties in the absorbed dose to water when measured in 
plastic have been minimised. 
3.5 Conclusions 
The CC04 cylindrical ionisation chamber used in this research project has been shown to accurately 
measure absorbed dose to water in electron beams across the range of depths that are of clinical 
interest. 
The dose comparisons show that the Elekta Monaco® eMC algorithm is able to accurately predict the 
dose in a homogeneous plastic water phantom, using simple beam geometries. Differences between 
the DFw calculated data and the measured 𝐷𝑤 data in the IMRT phantom are within ± 3% for the 
9 MeV, 12 MeV and 15 MeV beams, while slightly larger discrepancies of up to 4.1% are observed 
for the 6 MeV beam.  
Reasons for the poorer level of agreement observed for the 6 MeV data include dose gradient effects 
and the higher uncertainty in the beam quality correction factor, 𝑘𝑄,𝑄𝑐𝑟𝑜𝑠𝑠, used for absorbed dose 
to water determination.  
Use of the CC04 cylindrical ionisation chamber with the application of a customised ODSF for the 
specific phantom material provides a robust dosimetry system for future measurements of absorbed 
dose in more complex scenarios. However, the larger discrepancies observed for the 6 MeV data 




4 Validation of dose to medium in the Elekta Monaco® eMC 
algorithm in tissue equivalent slab phantoms 
This chapter describes the final step required to address research question 1, whereby more clinically 
relevant scenarios are tested in the Elekta Monaco® eMC algorithm in terms of 𝐷𝑚. 
4.1 Introduction 
A comparison was performed between dose measured with the CC04 cylindrical ionisation chamber 
and dose calculated by the Elekta Monaco® eMC algorithm in phantoms comprising tissue equivalent 
plastic slabs of varying electron density. Simple cases (i.e. homogeneous phantoms representing a 
single tissue type) as well as a more complex, clinically realistic case (i.e. an inhomogeneous 
phantom comprising multiple tissue types) were investigated.  
The purpose of these measurements was to assess the ability of the Elekta Monaco® eMC algorithm 
to accurately predict 𝐷𝑚 in a range of commonly encountered tissue types, with the ultimate aim of 
validating that the Elekta Monaco® eMC 𝐷𝑚 calculation option has acceptable accuracy for clinical 
use. In order to calculate 𝐷𝑚 from measurements of ionisation in non-water equivalent media, the 





4.2 Materials and methods 
4.2.1 Radiation detector  
The radiation detector used for all measurements was the same IBA CC04 cylindrical ionisation 
chamber as that described in Chapter 3. For further details on the characteristics and the cross 
calibration of this detector, refer to Section 3.2.1.  
4.2.2 Tissue equivalent slab phantoms 
Four different types of Computerised Imaging Reference Systems Inc. (CIRS) tissue equivalent slabs 
provided a means to replicate various tissue types within the body. Table 4.1 lists the four tissue 
types used along with their physical densities, while Figure 4.1 shows the slabs. Data of the actual 
elemental compositions of the tissue equivalent slabs were not available from the vendor.  
The dimension of each individual slab is 20 cm x 20 cm, with varying thicknesses of 0.5 cm, 1 cm or 
2 cm. For each tissue type, there is a 2 cm thick slab with a pre-milled insert slot designed for point 
dose determination with a CC04 cylindrical ionisation chamber. The modular design of the various 








Tissue equivalent slab type 
Nominal physical density 
(g/cm3) 
Adipose 0.94 
Exhale lung 0.50 
Trabecular bone 1.16 
Cortical bone 1.91 
Table 4.1: The various tissue equivalent slabs used for depth-dose measurements and their nominal 
physical densities. 
 
Figure 4.1: The various tissue equivalent slabs used for depth-dose measurements. Top left: 
adipose; Top right: exhale lung; Bottom left: trabecular bone; Bottom right: cortical bone.   
The tissue equivalent slabs were stacked in isolation to create simple, homogeneous phantoms (for 






scenario. These two cases, referred to as “simple” and “complex”, are detailed in Section 4.2.2.1 and 
4.2.2.2 respectively.  
4.2.2.1 Simple: homogeneous tissue equivalent slab phantoms 
A simple, homogeneous tissue equivalent slab phantom was created for each of the four tissue types. 
Each phantom consisted of a stack of varying thickness tissue equivalent slabs (of the single tissue 
type), with a 5 cm thick plastic water slab below to provide backscatter. An example of such a 
phantom is shown for adipose in Figure 4.2.  
 
 
Figure 4.2: The adipose homogeneous tissue equivalent slab phantom as used for depth-dose 
measurements. 
4.2.2.2 Complex: inhomogeneous tissue equivalent slab phantom 
The complex, inhomogeneous tissue equivalent slab phantom was designed to replicate what would 












3 cm thickness of adipose, followed by a 1 cm thickness of trabecular bone, then a 4 cm thickness 
of exhale lung. As for the simple phantoms, a 5 cm thick plastic water slab was placed below to 
provide backscatter. The complex phantom is shown in Figure 4.3.  
 
Figure 4.3: The complex, inhomogeneous tissue equivalent slab phantom as used for depth-dose 
measurements. 
4.2.3 Electrometer 
As in Section 3.2.3, the electrometer used for all measurements was a Scandatronix Wellhofer Dose 
1 (serial number 16717) with a bias voltage of +300 V applied. A 60-second background reading was 
taken and subtracted from all subsequent measurements. The electrometer correction factor, 𝑘𝑒𝑙𝑒𝑐, 
















4.2.4 Electron beam energies 
Electron beam energies available for use in the local department are 6 MeV, 9 MeV, 12 MeV and 15 
MeV. All electron beams were investigated for the simple, homogeneous phantoms. However, 
measurements were taken only for the 12 MeV and 15 MeV beams in the case of the complex, 
inhomogeneous phantom. These two energies provided an acceptable distribution of dose with depth 
in the phantom and are typical of what is used clinically for electron breast boost treatments.  
4.2.5 Creation of treatment plans  
The tissue equivalent slab phantoms (both simple cases and the complex case) were scanned using 
a 64-slice Siemens SOMATOM Confidence CT scanner. Data was exported to the Monaco® TPS 
where a series of electron plans were created and dose calculations performed. The following steps 
were taken to create the treatment plans in the Elekta Monaco® eMC algorithm. 
• Each phantom was placed on the CT couch and individually scanned using one of the 
standard clinical protocols used in the department.  
• Each CT dataset was imported into the Monaco® TPS via DICOM-RT. 
• The external boundary of each CT dataset was contoured. The (empty) ion chamber insert 
slot was also contoured, with the RED overridden to the average RED of the tissue material. 
Initially, separate CT scans were taken with the CC04 ionisation chamber inserted within the 
phantoms at each of the measurement depths. However, significant artefacts were produced 
from a high density region of the chamber stem, which could not be adequately removed 
using artefact reduction algorithms. Therefore, CT scans were performed without the 




• Electron plans were created for each energy (in the case of the simple, homogeneous tissue 
equivalent slab phantoms) and for 12 MeV and 15 MeV only (in the case of the complex, 
inhomogeneous tissue equivalent slab phantom), using a 10 cm x 10 cm applicator, at 100 
cm SSD and gantry and collimator settings at 0°. 
• Dose calculations were performed in the Elekta Monaco® eMC algorithm by delivering 100 
MU, using the 𝐷𝑚 dose deposition option, with 1,000,000 histories and with a grid cell size 
of 0.1 cm. In the case of the simple phantom for cortical bone, a significant artefact was 
present around the empty ion chamber insert slot due to the contrast between the high 
density bone and the low density air cavity. This resulted in inaccurate RED values being 
assigned in the dose calculation in this artefact area. To overcome the effect of the artefact, 
a RED override (equal to the average RED of the remainder of the tissue material) was 
applied to the artefact area.  
•  Sagittal dose planes from each of the dose calculations were exported from the Monaco® 
TPS and subsequently imported into Microsoft Excel as text files.  
• Point doses were extracted from the Monaco® TPS dose plane data in Microsoft Excel at 
the ionisation chamber measurement points that were used in each phantom, with the 
effective point of measurement of the ionisation chamber (in water) taken into account.  
4.2.6 Phantom set-up and measurements (for both simple and complex cases) 
Each phantom was set up to the isocentre on the treatment couch, at 100 cm SSD and with the 
gantry and collimator set to 0°. Charge measurements were taken with the ionisation chamber at 




chamber was accounted for through the extraction depth in the Elekta Monaco® eMC dose 
calculations.  
Three 100 MU exposures were delivered for each measurement depth in each phantom and for each 
applicable energy. For each of the three exposures, a charge reading was taken with the results 
averaged (𝑀1).  
Temperature and pressure readings were taken at regular intervals during data collection, so the 
temperature and pressure correction factor, 𝑘𝑡𝑝, necessary for absorbed dose determination could 
be calculated.  
4.2.7 Dose calculation formalism (𝑫𝒎) 
The purpose of these measurements was to validate the accuracy of the dose deposited in the 
medium as predicted by the Elekta Monaco® eMC algorithm. Therefore, it was necessary to calculate 
the absorbed dose to medium, 𝐷𝑚,𝑄, from the charge measurements obtained in each phantom. The 
steps involved in determining the measured 𝐷𝑚,𝑄 are outlined in Section 4.2.7.1 – Section 4.2.7.5. 
4.2.7.1 Determination of overall depth-scaling factors and water equivalent depths 
Overall depth-scaling factors, ODSFs, were determined for each tissue type and each energy using 
a similar method to that described in Section 3.2.8. ODSFs were required so that water equivalent 
depths for each physical measurement depth in each phantom could be determined. Water 
equivalent depths were necessary in order to obtain water-to-air Spencer-Attix stopping power ratios, 




The PDI measurements performed (as described in Section 4.2.6) in each of the simple, 
homogeneous tissue equivalent slab phantoms were used for this purpose. The resulting PDI data 
for each phantom and each energy were compared with the corresponding PDI data as measured in 
water using the IBA Blue Phantom water tank (see Section 3.2.1 for further details). An ODSF for 
each tissue type and each electron energy was determined by applying various factors to the 
phantom measurement depths until the root mean square error between the PDIs measured in water 
and the PDIs measured in each of the tissue equivalent slab phantoms was minimised. 
In the case of the complex phantom measurements, where multiple tissue types were present, water 
equivalent depths were determined using a combination of the relevant ODSFs. 
4.2.7.2 Determination of absorbed dose to water 
Similarly to Section 3.2.7, the absorbed dose to water, 𝐷𝑤,𝑄, was determined from ionisation 
measurements according to the IAEA TRS-398 protocol, using:  
𝐷𝑤,𝑄(𝑧) = 𝑀𝑄 (𝑧) 𝑁𝐷,𝑤,𝑄𝑐𝑟𝑜𝑠𝑠 𝑘𝑄,𝑄𝑐𝑟𝑜𝑠𝑠
(𝑠𝑤,𝑎𝑖𝑟)𝑄𝑧
(𝑠𝑤,𝑎𝑖𝑟)𝑄 𝑧𝑟𝑒𝑓
      [4.1] 
where: 
𝑀𝑄 = 𝑀1 𝑘𝑡𝑝 𝑘𝑠 𝑘𝑝𝑜𝑙 𝑘𝑒𝑙𝑒𝑐        [4.2] 
Values for the water-to-air Spencer-Attix stopping power ratios (at the water equivalent depths as 
determined in Section 4.2.7.1) were obtained from IAEA TRS-398 Table 7.V by interpolation between 
table entries. Chamber specific factors 𝑘𝑝𝑜𝑙, 𝑘𝑠  and 𝑁𝐷,𝑤,𝑄𝑐𝑟𝑜𝑠𝑠 were obtained during chamber 




4.2.7.3 Calculation of the most probable energy  
The most probable energy, (𝐸𝑝)𝑧, was determined at each water equivalent measurement depth 𝑧 
in each phantom and for each nominal beam energy under investigation. An estimate of the beam 
energy with depth in the phantom was necessary so that the tissue-to-water Spencer-Attix stopping 
power ratios, 𝑠𝑡𝑖𝑠𝑠𝑢𝑒,𝑤, could be obtained and, therefore, the 𝐷𝑚,𝑄 determined. 
Using the formalism of Khan (Khan & Gibbons 2014), the most probable energy at depth 𝑧 is given 
by:  
(𝐸𝑝)𝑧 = (𝐸𝑝)0 (1 −
𝑧
𝑅𝑝
)        [4.3] 
where 𝑧 is the water equivalent depth in the phantom (in cm), 𝑅𝑝 is the water equivalent practical 
range (in cm) for each nominal beam energy under investigation and (𝐸𝑝)0 is the most probable 
energy at the surface of the phantom. Using the formalism of Khan (Khan & Gibbons 2014), the most 
probable energy at the surface of the phantom is given by: 
(𝐸𝑝)0 = 𝐶1 + 𝐶2𝑅𝑝 + 𝐶3𝑅𝑝
2        [4.4] 
where 𝐶1 = 0.22 MeV, 𝐶2 = 1.98 MeV cm-1 and 𝐶3 = 1.98 MeV cm-2 
4.2.7.4 Determination of the stopping power ratio of tissue-to-water  
The most probable energies were used to determine the tissue-to-water Spencer-Attix stopping 
power ratios, 𝑠𝑡𝑖𝑠𝑠𝑢𝑒,𝑤 , at each water equivalent measurement depth. Stopping power data for each 




Standards and Technology (NIST) Stopping Power and Range Tables for Electrons (ESTAR) online 
database (National Institute of Standards and Technology 2018). 
Table 4.2 summarises the tissue substitute selected for each tissue equivalent slab type used to 
obtain the Spencer-Attix stopping power data and the equivalent tissue substitute used in the Elekta 
Monaco® eMC algorithm. The choice of the data source/tissue substitute used for each tissue 
equivalent slab type was based on obtaining the closest match to tissue substitutes used in the Elekta 
Monaco® eMC algorithm. For example, in the case of the adipose tissue equivalent slabs, stopping 
power data was obtained from ICRU Report 44 to match that used in the Elekta Monaco® eMC 
algorithm. Table 4.2 shows a discrepancy between the tissue substitutes used in the case of 
trabecular bone. The Elekta Monaco® eMC algorithm uses a weighted average (based on the RED 
of the material) of the ICRP Report 23 (Snyder et al. 1975) Cartilage and Bone tissue substitutes. As 
the stopping power data for ICRP 23 Cartilage could not be obtained, the next best match (ICRU 44 
Skeleton – Cartilage) was instead selected.  
In the case of the complex phantom measurements, where multiple tissue types were present, the 










Tissue equivalent slab type 
Measurements - tissue 
substitute used to obtain 
tissue stopping power data 
Monaco® eMC - tissue 
substitute used to obtain 
tissue stopping power data 
Adipose ICRU 44 Adipose ICRU 44 Adipose 
Exhale lung ICRU 44 Lung ICRU 44 Lung 
Trabecular bone ICRU 44 Skeleton - Cartilage 
Weighted average of ICRP 23 
Cartilage and ICRP 23 Bone 
Cortical bone 
ICRP 23 Cortical Bone (via 
ESTAR) 
ICRP 23 Bone 
Table 4.2: The tissue substitutes used to obtain Spencer-Attix stopping power data for each tissue 
equivalent slab type and the equivalent tissue substitute used in the Elekta Monaco® eMC algorithm.   
4.2.7.5 Determination of the absorbed dose to medium  
The absorbed dose to medium, 𝐷𝑚,𝑄, at each physical measurement depth 𝑧 in each phantom was 
calculated using: 
𝐷𝑚,𝑄(𝑧) = 𝐷𝑤,𝑄(𝑧) (𝑠𝑡𝑖𝑠𝑠𝑢𝑒,𝑤)𝑧           [4.5] 
 
4.3 Results 
4.3.1 Overall depth-scaling factors for each tissue equivalent slab type 
PDI measurements obtained using the CC04 ionisation chamber in water and in each of the simple, 
homogeneous tissue equivalent slab phantoms for all electron energies are shown in Figure 4.4 - 
Figure 4.7 for adipose, exhale lung, trabecular bone and cortical bone respectively. PDI data with the 





Figure 4.4: PDI measurements using the CC04 ionisation chamber in water (solid green curve) and 
in the simple, adipose phantom (solid red curve) for all electron energies. Also plotted is the PDI data 
as measured in the simple, adipose phantom with the optimal ODSF applied to the physical 
measurement depths (dashed red curve). 
 
Figure 4.5: PDI measurements using the CC04 ionisation chamber in water (solid green curve) and 
in the simple, exhale lung phantom (solid red curve) for all electron energies. Also plotted is the PDI 
data as measured in the simple, exhale lung phantom with the optimal ODSF applied to the physical 





Figure 4.6: PDI measurements using the CC04 ionisation chamber in water (solid green curve) and 
in the simple, trabecular bone phantom (solid red curve) for all electron energies. Also plotted is the 
PDI data as measured in the simple, trabecular bone phantom with the optimal ODSF applied to the 
physical measurement depths (dashed red curve). 
 
Figure 4.7: PDI measurements using the CC04 ionisation chamber in water (solid green curve) and 
in the simple, cortical bone phantom (solid red curve) for all electron energies. Also plotted is the PDI 
data as measured in the simple, cortical bone phantom with the optimal ODSF applied to the physical 




These figures show that for adipose, being the most water equivalent tissue type, the measured data 
points mostly cover the full range of the PDI curve and, therefore, the ODSFs can be estimated with 
a high degree of confidence. In contrast, for the more anomalous tissue types, there was difficulty in 
either measuring the full range of the PDI curve due to insufficient tissue material thickness (e.g. 
exhale lung and trabecular bone, particularly at higher energies) or obtaining adequate measurement 
resolution in the PDI curve due to the sharp dose fall-off with depth (e.g. cortical bone, particularly at 
low energies). In these cases, it follows that a higher level of uncertainty would be expected with 
these ODSFs.  
Table 4.3 summarises the ODSFs obtained for each tissue type and for each electron energy. There 
is a slight increase in the ODSFs with electron energy for adipose and trabecular bone, while a more 
pronounced variation in these factors is observed for cortical bone and exhale lung i.e. those tissue 
types with more anomalous densities compared with water.  
 










Adipose 0.86 ± 1% 0.87 ± 1% 0.89 ± 1% 0.92 ± 1% 
Exhale lung 0.48 ± 1% 0.49 ± 2% 0.56 ± 2% 0.67 ± 2% 
Trabecular bone 1.08 ± 1% 1.11 ± 1% 1.13 ± 2% 1.13 ± 2% 
Cortical bone 1.61 ± 2% 1.70 ± 1% 1.76 ± 1% 1.79 ± 1% 
Table 4.3: The ODSFs obtained for each tissue equivalent slab type and each electron energy. The 
ODSFs were determined by applying various factors to the physical measurement depths until the 
root mean square error between the PDIs measured in water and the PDIs measured in each of the 




4.3.2 Comparison between Elekta Monaco® eMC dose calculations and measured 𝑫𝒎 in the 
simple phantoms 
Results comparing the level of agreement between the Elekta Monaco® eMC 𝐷𝑚 dose calculations 
and the 𝐷𝑚 as measured in the simple, homogeneous tissue equivalent slab phantoms for all 
energies are shown in Figure 4.8 - Figure 4.11 for adipose, exhale lung, trabecular bone and cortical 
bone respectively. Table 4.4 quantifies the differences observed for each of the phantoms.  
While water equivalent depths were necessary in order to determine stopping power ratios for the 
calculation of 𝐷𝑚,𝑄(𝑧), the dose data presented in Figure 4.8 - Figure 4.11 are plotted against the 
physical depths in the phantoms.  
 
Figure 4.8: Comparison of the Elekta Monaco® eMC 𝐷𝑚 dose calculation and the 𝐷𝑚 as measured 





Figure 4.9: Comparison of the Elekta Monaco® eMC 𝐷𝑚 dose calculation and the 𝐷𝑚 as measured 
in the simple, exhale lung phantom for all electron beam energies. 
 
Figure 4.10: Comparison of the Elekta Monaco® eMC 𝐷𝑚 dose calculation and the 𝐷𝑚 as measured 





Figure 4.11: Comparison of the Elekta Monaco® eMC 𝐷𝑚 dose calculation and the 𝐷𝑚 as measured 





Table 4.4: Differences between the Elekta Monaco® eMC 𝐷𝑚 dose calculations and the 𝐷𝑚 as 
measured in the simple, tissue equivalent slab phantoms for all electron beam energies (normalised 
to the maximum 𝐷𝑚 calculated dose). Difference values exceeding 7% are highlighted in red, while 
those between 3 - 7% are highlighted in orange.  
Differences between the calculated and measured data are mostly within ± 3% for the adipose, 
exhale lung and trabecular bone phantoms. For these phantoms, a small number of data points have 
greater discrepancies, the largest being 6.2% at depth in the exhale lung phantom for 6 MeV.  
However, much larger discrepancies are observed for the cortical bone phantom where close to 90% 
of data points have discrepancies greater than ± 3%. Differences tend to increase as the energy 

























0.9 -2.7% 0.9 1.5% 0.9 0.4% 0.9 0.9%
1.4 -1.0% 1.4 -1.1% 1.9 0.1% 1.4 2.7%
1.9 0.6% 1.9 -0.8% 2.9 0.9% 1.9 3.5%
2.4 1.3% 2.4 -1.2% 3.4 0.4% 2.4 2.3%
2.9 1.0% 2.9 1.5% 3.9 -0.6% 2.9 2.6%
3.4 4.2% 4.4 0.7% 3.4 0.5%
3.9 4.5% 4.9 2.3% 3.9 -0.4%
4.4 2.6% 5.4 1.4% 4.9 1.5%
5.9 0.9% 5.9 4.2%
0.9 -1.0% 0.9 -0.1% 0.9 -1.9% 0.9 -1.5%
1.9 -0.2% 1.9 -0.3% 1.9 0.2% 3.9 -0.8%
2.9 1.3% 2.9 -1.5% 2.9 -1.2% 5.9 -3.4%
3.9 2.3% 3.9 -0.6% 3.9 -0.9%
4.9 2.3% 4.9 1.6% 4.9 -1.5%
5.9 6.2% 5.9 1.1% 5.9 -2.2%
0.9 -1.4% 0.9 -3.7% 0.9 -0.8% 0.9 -0.3%
1.4 0.2% 1.4 -2.3% 1.4 -1.0% 1.9 0.1%
1.9 -1.2% 1.9 -1.0% 1.9 -1.8% 2.9 -1.1%
2.4 -1.4% 2.4 2.0% 2.4 -2.1% 3.4 -0.2%
2.9 1.9% 2.9 -1.0%
3.4 1.2% 3.4 -0.3%
0.9 0.0% 0.9 -6.3% 0.9 -7.3% 0.9 -8.0%
1.4 3.3% 1.4 -0.3% 1.4 -9.5% 1.4 -7.6%
1.9 6.7% 1.9 -3.1% 1.9 -8.2%
2.4 6.0% 2.4 4.4% 2.4 -5.2%










































4.3.3 Comparison between Elekta Monaco® eMC dose calculations and measured 𝑫𝒎 in the 
complex phantom 
Results comparing the level of agreement between the Elekta Monaco® eMC 𝐷𝑚 dose calculations 
and the 𝐷𝑚 as measured in the complex, inhomogeneous tissue equivalent slab phantom are shown 
in Figure 4.12 for both the 12 MeV and 15 MeV beams. For reference, Elekta Monaco® eMC 𝐷𝑤 data 
are also shown to demonstrate what would be delivered in the case where 𝐷𝑚 based calculations 
were not available. Table 4.5 quantifies the differences observed between the Elekta Monaco® eMC 
dose calculations and the measured 𝐷𝑚.  
While water equivalent depths were necessary in order to determine stopping power ratios for the 
calculation of 𝐷𝑚,𝑄(𝑧), the dose data presented in Figure 4.12 are plotted against the physical 






Figure 4.12: Comparison of the Elekta Monaco® eMC 𝐷𝑚 dose calculation and the 𝐷𝑚 as measured 
in the complex, inhomogeneous tissue equivalent slab phantom for 12 MeV and 15 MeV. For 
reference, Elekta Monaco® eMC 𝐷𝑤 data are also shown. 
 
Table 4.5: Differences between the Elekta Monaco® eMC 𝐷𝑚 dose calculations and the 𝐷𝑚 as 
measured in the complex, inhomogeneous tissue equivalent slab phantom for 12 MeV and 15 MeV 
(normalised to the maximum 𝐷𝑚 calculated dose). Difference values between 3 - 7% are highlighted 
in orange. Also shown are the differences between the Elekta Monaco® eMC dose calculations in 





















0.9 Adipose 2.0% 0.9% 0.9 Adipose 1.8% 0.9%
1.9 Adipose 0.3% 0.9% 1.9 Adipose -1.7% 0.9%
4.9 Exhale Lung 3.4% 0.9% 4.9 Exhale Lung 0.3% 1.4%
5.9 Exhale Lung 2.4% 0.5% 5.9 Exhale Lung 0.2% 1.2%





Differences between the Elekta Monaco® eMC 𝐷𝑚 dose calculations and the 𝐷𝑚 data as measured 
in the complex phantom are mostly within ± 3%. The largest discrepancy observed is 3.4% in the 
case of the 12 MeV beam. This data point was located within exhale lung, closest to the trabecular 
bone interface.  
Differences between the Elekta Monaco® eMC calculated doses in terms of 𝐷𝑤 and 𝐷𝑚 are all less 
than 1.5%.  
4.4 Discussion 
The agreement between 𝐷𝑚 measured in three of the simple, tissue equivalent slab phantoms 
(adipose, exhale lung and trabecular bone) with the Elekta Monaco® eMC 𝐷𝑚 calculated data is 
mostly within ± 3% for all energies. For these phantoms, data points exceeding a ± 3% discrepancy 
are limited to less than 10% of the total measurement points investigated, while no data points exceed 
the 7% tolerance as recommended by the AAPM for electron dose calculation algorithms in 
inhomogeneous media (Smilowitz et al. 2015).  
There is no specific tolerance recommended for basic TPS validation in non-water equivalent 
homogeneous phantoms and, furthermore, no tolerance specified for validation in terms of 𝐷𝑚. 
However, the results presented here suggest that, in the majority of cases, the Elekta Monaco® eMC 
algorithm is able to accurately predict 𝐷𝑚 in simple phantoms of a single tissue type. Additionally, 
these results show that the novel method devised here for 𝐷𝑚 calculation using water equivalent 
depths provides a robust dosimetry system in most cases.  
A clear exception is observed for the simple, cortical bone phantom, where differences between the 




largest discrepancies (up to ± 10.7%) observed for higher beam energies. The results for cortical 
bone may be attributed to the high density of the material (i.e. 1.91 g/cm3). It is expected that cortical 
bone would have very different scattering properties as compared with those of water, resulting in a 
much greater lateral spread of the beam as it traverses the medium, significantly affecting the dose. 
Therefore, the results obtained for the simple, cortical bone phantom highlight the weakness of the 
water equivalent depth method for 𝐷𝑚 determination in cases where materials are significantly 
different in density from water. 
Additionally, the effective point of measurement of the ionisation chamber is unknown in non-water 
equivalent materials. However, in all of the data presented here, the effective point of measurement 
has been assumed to be as if the chamber was in water (i.e. 1 mm upstream of the cavity centre). In 
less dense materials such as adipose and exhale lung, the effective point of measurement of the 
chamber would move toward the centre of the chamber, while for denser materials such as trabecular 
and cortical bone, the effective point of measurement of the chamber would be closer to the surface 
of the phantom. In the case of high density cortical bone, the shift in the effective point of 
measurement could be significant and, therefore, may contribute to the poorer results observed for 
the simple, cortical bone phantom. Additionally, the effective point of measurement may be depth 
dependant as the mean square scattering angle of electrons increases with depth.  
The PDI curves (Figure 4.4 - Figure 4.7) suggest an increased level of uncertainty in the ODSFs in 
some cases (e.g. exhale lung and trabecular bone, particularly at higher energies and cortical bone, 
particularly at low energies). However, this source of error is unlikely to have a significant bearing on 
the measured versus calculated 𝐷𝑚 comparisons. The ODSFs were used to calculate water 
equivalent depths, which were in turn used to determine the energy of the beam at these depths so 
that stopping power data for each tissue type could be obtained. While stopping power data did vary 




energy. Therefore, any uncertainty in the estimated most probable energy and ODSFs is unlikely to 
translate into significant errors in the tissue-to-water stopping power ratios. For example, given a 2% 
uncertainty in the ODSF, the error in tissue-to-water stopping power ratios is estimated to be less 
than 0.3%. Furthermore, the use of monoenergetic stopping power data (rather than more accurate 
stopping power data based on a polyenergetic spectrum) is unlikely to have a significant impact on 
the measured versus calculated 𝐷𝑚 comparisons. 
In the case of the complex, inhomogeneous phantom, excellent agreement was observed between 
the measured 𝐷𝑚 and the Elekta Monaco® eMC 𝐷𝑚 calculated data. All data points investigated for 
both energies were well within the 7% tolerance as recommended by the AAPM for electron dose 
calculation algorithms in inhomogeneous media (Smilowitz et al. 2015). These results show that the 
Elekta Monaco® eMC algorithm is able to accurately predict 𝐷𝑚 in the clinically realistic scenario 
considered. Furthermore, these results add further weight to the accuracy of the water equivalent 
depth method developed in this research project to calculate 𝐷𝑚 from measurements of ionisation 
in tissue types that are not significantly different in density from water. 
The results obtained for the complex, inhomogeneous phantom also show only small differences 
(less than 1.5%) between the Elekta Monaco® eMC doses calculated in terms of 𝐷𝑚 and 𝐷𝑤. 
Significant differences would only be expected for cases involving materials with a chemical 
composition substantially different from that of water (e.g. cortical bone). Therefore, in most clinical 
scenarios (i.e. those involving near water equivalent media), the differences between dose calculated 
in terms of 𝐷𝑚 and 𝐷𝑤 are insignificant. However, clinical practice shows that significant differences 
in the number of MU to be delivered to patients based on a 𝐷𝑤 measured output factor and that 
calculated in terms of 𝐷𝑚 do in fact occur. (This aspect of the research project is discussed in more 
detail in Section 5.3.1). It is likely that these differences are primarily due to the increase in accuracy 




in accuracy results from the use of the patient CT dataset to obtain the patient contour and density 
information, as opposed to the use of a measured output factor based on a flat, homogeneous plastic 
water slab phantom.  
4.5 Conclusions 
The results show that the 𝐷𝑚 calculation in the Elekta Monaco® eMC algorithm is able to accurately 
predict the dose in most cases (both simple and complex) involving non-water equivalent media. In 
the case of simple, homogeneous phantoms involving a single tissue type of adipose, exhale lung or 
trabecular bone, the level of agreement between the measured 𝐷𝑚 and the Elekta Monaco® eMC 
𝐷𝑚 calculated data is mostly within ± 3%. In the more clinically realistic case involving three tissue 
types, agreement was found to be within ± 3.4%. However, large discrepancies of up to ± 10.7% 
were observed for the simple, cortical bone phantom.  
The novel method devised here for 𝐷𝑚 determination using water equivalent depths provides a 
robust dosimetry system in cases where tissue types are not significantly different in density from 
water (i.e. > 0.5 g/cm3 and < 1.5 g/cm3). However, the poor cortical bone results highlight the 
weakness of the water equivalent depth method in high density tissues. This is likely due to the 
different scattering properties of cortical bone as compared with those of water and the unknown 
effective point of measurement of the ionisation chamber when in non-water equivalent materials. 
While it has not been experimentally verified, it can be expected that similar behaviour would be 
observed for very low density materials such as inhale lung (density 0.2 g/cm3).  
The 𝐷𝑚 validation results presented here suggest that the Elekta Monaco® eMC 𝐷𝑚 calculation is 
accurate in most of the clinical scenarios considered. However, in order to fully validate the algorithm, 




validation method would involve full Monte Carlo modelling to correctly account for the unique 
scattering properties of the materials and to determine the energy spectrum and polyenergetic tissue-
to-water stopping power ratios at each measurement depth. However, this work is beyond the scope 
of the project.  
In most cases, the difference in the number of MU to be delivered in patient treatments based on 
measured output factors in water compared with those calculated in terms of 𝐷𝑚 is likely due to the 
increase in accuracy of the dose calculation (e.g. more realistic patient geometry), rather than 




5 Statistical analysis of patient acute toxicity data 
This chapter addresses research question 2 by examining the effect on patient outcomes from using 
the Elekta Monaco® eMC 𝐷𝑚-based MU in clinical treatments. 
5.1 Introduction 
A statistical analysis of patient data was undertaken to assess the effect of the change in clinical 
practice from using measured 𝐷𝑤-based MU (i.e. MU measured in a flat, homogenous plastic water 
phantom) to calculated 𝐷𝑚-based MU in electron treatments in terms of patient acute skin toxicity. 
Patient acute toxicity and treatment-related data from the electronic medical record (eMR) have been 
collected and summarised for two purposes. 
• Undertaking a cohort study to determine whether there is a statistically significant difference 
in acute skin toxicity for patients treated with the measured 𝐷𝑤-based MU compared with a 
similar cohort of patients treated with the Elekta Monaco® eMC 𝐷𝑚-based MU. This 
determination will be achieved using the Cochran-Armitage test for linear trend. 
• Assessing the relationship between acute toxicity grade and various clinical factors to 
identify predictors of radiation-induced acute skin toxicity. This assessment will be achieved 




5.2 Materials and methods 
5.2.1 Patient data collection and summary statistics 
The eMR used at MNCCI is Elekta’s MOSAIQ®. A full list of patients treated with electrons at MNCCI 
from 2016 (when the Elekta Monaco® eMC algorithm was commissioned for clinical use) up until 
2019 was extracted from MOSAIQ®. Patients recruited into the cohort study needed to meet the 
following eligibility criteria. 
• Have been treated with electrons, using any of the available electron beams: 6 MeV, 9 MeV, 
12 MeV, 15 MeV or 18 MeV. 
• Have been treated for skin cancer: Squamous cell carcinoma (SCC), Basal cell carcinoma 
(BCC), Melanoma or skin cancer - other. 
• Have no concurrent photon treatment. 
• Have maximum baseline toxicity grades of less than 2. 
• Have at least one acute toxicity assessment recorded during their treatment or within 
90 days of their treatment finish date. 
• Have been treated at any one of the three MNCCI cancer centres: Port Macquarie, 
Coffs Harbour or Lismore. 
Patients treated with electron breast boosts have not been included in the cohort study as these 
patients also undergo treatment with photon fields. To reduce the risk of confounding factors caused 
by the photon fields, the decision was made to limit the cohort study to only skin cancer patients 




Once recruited, the patients were classified into either cohort 1 or cohort 2 based on whether they 
were treated using the measured 𝐷𝑤-based MU or with the 𝐷𝑚-based MU as calculated in the Elekta 
Monaco® eMC algorithm. Table 5.1 outlines the cohort 1 and cohort 2 definitions. 
 
Cohort name Description 
Approximate date range 
of patient treatment 
Cohort 1 
Eligible patients treated with measured 
𝐷𝑤-based MU 
2016 – Mid 2018 
Cohort 2 
Eligible patients treated with 𝐷𝑚-based MU as 
calculated in the Elekta Monaco® eMC algorithm 
Mid 2018 – Mid 2019 
Table 5.1: Definitions of cohort 1 and cohort 2.  
For each patient recruited to the cohort study, the following treatment-related data and general patient 
information were extracted from MOSAIQ®: 
• Radiotherapy treatment start date 
• Principal diagnosis code 
• Care plan name (i.e. the cancer type to be treated) 
• Patient name and unique identifying number 
• Cancer centre of treatment 
• Electron beam energy used for treatment 
• Gender 
• Age 
• Specific site treated (e.g. ear, scalp, nose) 
• Prescription dose, number of fractions, isodose used for prescription 




• MU calculation method: measured 𝐷𝑤-based or calculated 𝐷𝑚-based 
To record information on patient acute toxicity, MNCCI uses the Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4 (U.S Department of Health and Human Services 2009). In this 
guideline, adverse events are defined as: 
“Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporarily associated with the use of a medical treatment or procedure that may or may not 
be considered related to the medical treatment or procedure. An adverse event is a term that is a 
unique representation of a specific event used for medical documentation and scientific analyses.” 
In the context of this study, adverse events can be thought of as different categories of skin acute 
toxicity signs and symptoms that result from the patient’s electron treatment. The adverse events 
assessed in this study were rash, infection, pain, telangiectasia, soft tissue fibrosis, alopecia and skin 
ulceration. Each of these adverse events is described in Table 5.2. 
According to the CTCAE guidelines, each adverse event is graded for severity between 1 and 5. 








A disorder characterised by the presence of macules 
(flat) and papules (elevated). 
Infection 
A disorder characterised by an infectious process 
involving the skin. 
Pain 
A disorder characterised by a marked discomfort 
sensation in the skin. 
Telangiectasia 
A disorder characterised by local dilatation of small 
vessels resulting in red discoloration of the skin or 
mucous membranes.  
Soft tissue fibrosis 
A disorder characterised by fibrotic degeneration of 
the superficial soft tissues.  
Alopecia 
A disorder characterised by a decrease in density of 
hair compared to normal for a given individual at a 
given age and body location.  
Skin ulceration 
A disorder characterised by circumscribed, 
inflammatory and necrotic erosive lesion on the skin.  
Table 5.2: Definitions of skin-related adverse events, taken from CTCAE Version 4 (U.S Department 
of Health and Human Services 2009). 
Grade of adverse 
event 
Description of grade 
Grade 1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
Grade 2 
Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental Activities of Daily Living (ADL). * 
Grade 3 
Severe or medically significant but not immediately life-threatening; 
hospitalisation or prolongation of hospitalisation indicated; disabling; 
limiting self-care ADL. ** 
Grade 4 Life threatening consequences; urgent intervention indicated.  
Grade 5 Death related to the adverse event. 
Table 5.3: General definitions of severity grades, taken from CTCAE Version 4 (U.S Department of 
Health and Human Services 2009), where *Instrumental ADL refer to preparing meals, shopping for 
groceries or clothes, using the telephone, managing money, etc. and **Self-care ADL refer to bathing, 




At MNCCI, a baseline toxicity assessment is carried out before the patient’s radiotherapy treatment 
start date, whereby each of the adverse events in Table 5.2 is given a severity score using the 
definitions in Table 5.3. The baseline toxicity assessment assesses and records any skin toxicities 
the patient may have that are not caused by the radiation treatment (but may or may not be related 
to the cancer being treated). Acute toxicity assessments then occur at regular intervals during the 
patient’s treatment, and up to 90 days after their treatment is completed. The overall frequency of 
acute toxicity assessments is approximately every 2 - 3 weeks.  
For the purposes of patient data collection and analysis, the maximum scores for both baseline and 
acute toxicity assessments were recorded for each adverse event. For example, a patient may have 
had 10 acute toxicity assessments recorded during and after their treatment, with rash grades varying 
between 1 and 3. In this example, the grade that would be recorded for the acute toxicity assessment 
rash adverse event would be 3.  
All patient data was collated and stored in a Microsoft Excel spreadsheet. Summary statistics, relating 
to general patient information and treatment characteristics were performed in Microsoft Excel to gain 
an overall impression of the dataset.  
5.2.2 Cochran-Armitage test for linear trend  
In order to determine whether there is a statistically significant difference in acute toxicity for patients 
treated with the measured 𝐷𝑤-based MU as compared with patients treated with the Elekta Monaco® 
eMC 𝐷𝑚-based MU, the Cochran-Armitage test for linear trend (Armitage 1955; Cochran 1954) was 




This statistical test is a modified form of a chi-squared test and is often used in epidemiology and 
dose-response studies to test for trends among binomial proportions. Its purpose is to investigate the 
presence of an association between a variable with two categories (i.e. a binary variable) and an 
explanatory variable with n categories. In the context of this cohort study, the binary variable is cohort 
(i.e. either cohort 1 or cohort 2) while the explanatory variable is the acute toxicity grade. The acute 
toxicity grade takes into account the baseline toxicity score: a subtraction was performed between 
the maximum acute toxicity grade and the maximum baseline grade, herein referred to as the 
“difference grade”.  
The test was performed for each adverse event individually, and for all adverse events combined. 
The input data for the test were provided as “2 x n” tables of percentage frequency count for each 
adverse event, and for all adverse events combined i.e. in each case, the percentage of patients 
experiencing each of the various difference grades, n, are tabulated for both cohort 1 and cohort 2. 
These data tables were entered directly into the Genstat software for processing.  
The null hypothesis, H0, for the Cochran-Armitage test for linear trend is the hypothesis of no trend, 
which means that the binomial proportion is the same for all levels of the explanatory variable. The 
alternative hypothesis, H1, is that there is a linear trend in binomial proportions across increasing 
levels of the explanatory variable. The results of the test are presented as p-values: p-values under 
0.05, corresponding to a 95% confidence interval (CI), are considered statistically significant (i.e. 
where the null hypothesis can be rejected). For p-values larger than 0.05, the null hypothesis cannot 




5.2.3 Binary logistic regression models  
A binary logistic regression model for each adverse event was created in IBM® SPSS software to 
assess the effect of various predictors on acute toxicity grade. Binary logistic regression works by 
assessing the relationship between a dependent binary variable (i.e. the “outcome”) and one or more 
independent variables called predictors (i.e. explanatory variables that are suspected of influencing 
the outcome of the dependent variable). The goal of logistic regression is to find the best fitting model 
to describe the relationship between the dependent binary variable of interest and the set of 
independent predictor/explanatory variables. 
Figure 5.1 shows the concept of binary logistic regression. For this analysis, the dependent binary 
variable is acute toxicity for the specific adverse event (i.e. present or not present), while the 
predictors include cohort (i.e. cohort 1 or cohort 2), baseline toxicity for the specific adverse event 
(i.e. either present or not present) and “tissue category”.  
Tissue category has three possible classifications: soft tissue, bone or air. It essentially describes if 
the patient's treatment site consists mostly of soft tissue or has bone or air inhomogeneities present. 
For example, a scalp treatment would be categorised as bone, an ear/nose treatment would be 
categorised as air while an abdomen treatment would be considered soft tissue. The rationale for this 
predictor was that such tissue inhomogeneities may lead to larger MU discrepancies between 𝐷𝑤 





Figure 5.1: The use of binary logistic regression in the context of this statistical analysis (image 
modified from Scale (2020)). 
The input data used in IBM® SPSS to create the binary logistic regression models for each adverse 
event are set out here. 
• The binary outcome variable was coded as 0 = acute toxicity not present (i.e. the maximum 
acute toxicity grade was 0). 
• The binary outcome variable was coded as 1 = acute toxicity present (i.e. the maximum 
acute toxicity grade was ≥ 1). 
• The predictor variable of baseline grade was coded as 0 = baseline toxicity not present (i.e. 
the maximum baseline toxicity grade was 0). 
• The predictor variable of baseline grade was coded as 1 = baseline toxicity present (i.e. the 




• The predictor variable of cohort was coded as 0 for cohort 1 and coded as 1 for cohort 2 (i.e. 
cohort 1 acts as the reference category). 
• The polychotomous predictor variable of tissue category was coded as 0 = soft tissue, 1 = 
bone, 2 = air, with soft tissue acting as the reference category. 
The model output data are given in the form of an adjusted odds ratio, Exp B, with lower and upper 
limits of the 95% CI associated with the adjusted odds ratio, for each of the predictor variables. A 
p-value is also reported. The model output results for each predictor variable are interpreted in the 
following way (Scale 2020). 
• If the 95% CI associated with the adjusted odds ratio crosses over 1.0, then there is a non-
significant association. The p-value associated with these variables will also be greater than 
0.05.  
• If the adjusted odds ratio is above 1.0 and the 95% CI is entirely above 1.0, then exposure 
to the predictor increases the odds of the outcome. 
• If the adjusted odds ratio is below 1.0 and the 95% CI is entirely below 1.0, then exposure 
to the predictor decreases the odds of the outcome. 
The binary logistic regression model for each adverse event also produces scatter plots of the raw 
residuals, which show the differences between the observed and predicted probabilities of the model, 
plotted against the predicted probability. These scatter plots help to subjectively assess the 
assumption of linearity in the model (and hence the validity of the model), based on the symmetry of 




In addition, normalised residuals are produced – these values can be used to identify outliers in the 
dataset. Generally, any observations in the model with a normalised residual with an absolute value 
larger than 2.6 (i.e. a z-score/standard deviation corresponding to an approximate CI of 99%) would 
be considered an outlier and, therefore, would warrant further investigation. The robustness of each 
model was assessed by temporarily excluding any observations in the models associated with these 
outliers and re-calculating the logistic regression. The percentage change in the newly obtained 
model coefficients, B, from the model coefficients using the full dataset was then assessed for each 
predictor variable and for each adverse event. For changes less than 10%, the model is considered 
to be robust. 
5.3 Results  
5.3.1 Summary statistics 
Table 5.4 summarises the basic clinical and treatment characteristics of the two cohorts. The total 
number of patients recruited into the study was 294 (from a possible total population of 413), with 
141 patients in cohort 1 and 153 patients in cohort 2. The average age of patients was similar across 
the two cohorts, with 76 years and 75 years for cohort 1 and cohort 2 respectively. In both cohorts, 
there was a much higher proportion of males (70-80%) to females (20-30%). Most patients were 
treated at the Port Macquarie cancer centre (47%), with smaller numbers recruited from the other 
two centres (30% for Coffs Harbour and 23% for Lismore). The most common skin cancer types 
treated were SCC and BCC with 61% and 34% of patients respectively. The use of the various 
electron beam energies was similar across the two cohorts, with the most commonly used energies 





Table 5.4: Basic clinical and treatment characteristics of patients recruited into the cohort study. 
Figure 5.2 shows the percentage of patients who were treated for different anatomical sites, in cohort 
1 and cohort 2. The most commonly treated anatomical sites were ear, scalp and forehead/temple 
for both cohorts. 
Clinical and treatment characteristics of patients
Cohort 1 Cohort 2
Patients (No.) 141 153
Age
Mean ± SD 76 ± 11 75 ± 10





Port Macquarie 87 51








6 MeV 64 74
9 MeV 63 58
12 MeV 13 16
15 MeV 1 3





Figure 5.2: The percentage of patients treated for different anatomical sites in cohort 1 and cohort 
2. 
While patients in cohort 1 were treated with the measured 𝐷𝑤-based MU, 𝐷𝑚-based dose 
calculations in the Elekta Monaco® eMC algorithm were also carried out for these patients, thereby 
providing a direct comparison between the measured 𝐷𝑤-based MU and the calculated 𝐷𝑚-based 
MU. This data is summarised in Figure 5.3. On average, the difference between the measured 
𝐷𝑤-based MU and the calculated 𝐷𝑚-based MU was 2.5% (with the 𝐷𝑚-based MU as calculated in 
the Elekta Monaco® eMC algorithm being higher). However, in certain cases, differences of up to 
20% were observed. Generally, these large differences were for cases involving high density cortical 
bone (such as in scalp treatments) or for cases involving air inhomogeneities (such as in nose and 





Figure 5.3: The difference between the measured 𝐷𝑤-based MU and the 𝐷𝑚-based MU as 
calculated in the Elekta Monaco® eMC algorithm (data only applicable to patients in cohort 1).  
Table 5.5 summarises the patient acute toxicity assessment data for both cohorts. The data show 
that no patients experienced either grade 4 or grade 5 acute skin reactions. Grade 2 was the most 
common maximum grade recorded across both cohorts, experienced by 68% of all patients. This 
was followed by grade 1 (19% of all patients) and grade 3 (12% of all patients). The average number 
of acute toxicity assessments recorded per patient was 6 in cohort 1 and 5 in cohort 2.  
 
 
Table 5.5: Incidence of radiation-induced acute skin toxicity for all adverse events combined.  
No toxicity 1 2 3 4 5
Cohort 1 1% 18% 66% 15% 0% 0%
Cohort 2 1% 19% 71% 10% 0% 0%
Total (No.) 2 55 201 36 0 0




A more detailed summary of the patient acute toxicity assessment data, broken down into each 
adverse event, is presented in Table 5.6, and shown graphically in Figure 5.4 - Figure 5.10. The most 







Table 5.6: The percentage of patients experiencing either no toxicity or maximum acute toxicity grades of 1 to 5, in each cohort and for each adverse event.  
 
 
Adverse Event Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2
Rash 1% 1% 21% 22% 64% 67% 14% 10% 0% 0% 0% 0%
Infection 82% 88% 15% 7% 4% 5% 0% 0% 0% 0% 0% 0%
Pain 34% 50% 60% 44% 6% 6% 0% 0% 0% 0% 0% 0%
Telangiectasia 94% 93% 6% 7% 0% 0% 0% 0% 0% 0% 0% 0%
Soft tissue fibrosis 67% 77% 32% 21% 1% 2% 0% 0% 0% 0% 0% 0%
Alopecia 67% 69% 31% 31% 1% 1% 0% 0% 0% 0% 0% 0%
Skin ulceration 87% 89% 6% 4% 7% 7% 1% 1% 0% 0% 0% 0%





Figure 5.4: The percentage of patients in each cohort experiencing either no toxicity or maximum 
acute skin toxicity grades of 1 to 5 for the rash adverse event. 
 
Figure 5.5: The percentage of patients in each cohort experiencing either no toxicity or maximum 





Figure 5.6: The percentage of patients in each cohort experiencing either no toxicity or maximum 
acute skin toxicity grades of 1 to 5 for the pain adverse event. 
 
Figure 5.7: The percentage of patients in each cohort experiencing either no toxicity or maximum 





Figure 5.8: The percentage of patients in each cohort experiencing either no toxicity or maximum 
acute skin toxicity grades of 1 to 5 for the soft tissue fibrosis adverse event. 
 
Figure 5.9: The percentage of patients in each cohort experiencing either no toxicity or maximum 





Figure 5.10: The percentage of patients in each cohort experiencing either no toxicity or maximum 
acute skin toxicity grades of 1 to 5 for the skin ulceration adverse event. 
5.3.2 Cochran-Armitage test for linear trend 
Table 5.7 shows the results from the Cochran-Armitage test for linear trend in the form of p-values. 
None of the adverse events returned p-values under 0.05, showing there is no statistically significant 
difference in acute skin toxicity for patients treated with the measured 𝐷𝑤-based MU compared with 














Soft tissue fibrosis 0.765 
Alopecia 0.994 
Skin ulceration 0.869 
ALL EVENTS 0.646 
Table 5.7: p-values from the Cochran-Armitage test for linear trend, as calculated in Genstat, for 
each individual adverse event and for all events combined. 
5.3.3 Binary logistic regression models  
Table 5.8 summarises the results of the binary logistic regression analysis for each adverse event. 
By interpreting the adjusted odds ratios and associated upper and lower limits of the 95% CIs, the 
following significant results were obtained from the models. 
• Baseline toxicity predictor variable: for multiple adverse events (infection, pain, 
telangiectasia, soft tissue fibrosis and alopecia), there is a significant correlation between 
baseline toxicity grade and acute toxicity grade. The models show that having a higher 
baseline toxicity grade increases the chances of having increased levels of acute toxicity. 
• Cohort predictor variable: for the pain adverse event, there is a significant correlation 
between cohort and acute toxicity grade. The model shows that patients in cohort 2 




• Tissue category predictor variable: for the pain and alopecia adverse events, there is a 
significant correlation between bone-related treatment sites and acute toxicity grade. In 
terms of the pain adverse event, the model showed that patients with a bone treatment site 
were likely to experience lower levels of acute toxicity, while for the alopecia adverse event, 
patients were likely to experience increased acute toxicity.  
Figure 5.11 - Figure 5.17 show scatter plots of the raw residuals against the predicted probability for 
each adverse event. In all cases, linearity can be assumed given the points are mostly symmetric 
above and below a straight line and the points are mostly evenly distributed along a line. 
Table 5.9 summarises the number of outliers (i.e. normalised residuals with an absolute value larger 
than 2.6) in each of the models. All models had at least 1 outlier, with significant numbers observed 
for the telangiectasia and skin ulceration adverse events (15 and 26 outliers respectively). As 
described in Section 5.2.3, the binary logistic regression models were calculated with the outliers 
excluded, so that the model coefficients could be compared with the full dataset and, therefore, the 
degree of robustness of each model could be assessed. The final results from this test are 
summarised in the “Model Robust?” column of Table 5.8. Of the eight significant results obtained, 
three can be considered to be associated with a robust model. These are pain (cohort predictor 
variable), soft tissue fibrosis (baseline predictor variable) and alopecia (bone tissue category 
predictor variable).  
For the rash adverse event, the degree of model robustness could not be computed. This adverse 
event had two outliers: one from cohort 1 and one from cohort 2. These were the only model 
observations with the acute toxicity outcome variable of zero, meaning that after removal of these 




Therefore, the regression analysis could not be calculated as it requires exactly two values for the 





Table 5.8: A summary of results from the binary logistic regression models for each adverse event. Significant results are highlighted in green. 
Lower Upper
Rash
Cohort 3.40 0.19 62.08 No N/A
Baseline 1134403.92 0.00 No N/A
Tissue Category - Bone 22285346.96 0.00 No N/A
Tissue Category - Air 2.61 0.14 47.57 No N/A
Infection
Cohort 0.70 0.33 1.51 No Not Robust
Baseline 8.70 3.18 23.83 Yes Not Robust Having a higher baseline score increases the chance of having greater acute toxicity
Tissue Category - Bone 0.80 0.30 2.12 No Not Robust
Tissue Category - Air 1.05 0.40 2.72 No Robust
Pain
Cohort 0.58 0.35 0.98 Yes Robust Patients in cohort 2 have a decreased chance of having greater acute toxicity
Baseline 2.76 1.19 6.44 Yes Not Robust Having a higher baseline score increases the chance of having greater acute toxicity
Tissue Category - Bone 0.39 0.19 0.82 Yes Not Robust Patients with a bone treatment site have a decreased chance of having greater acute toxicity 
Tissue Category - Air 0.69 0.32 1.47 No Not Robust
Telangiectasia 
Cohort 1.20 0.43 3.37 No Not Robust
Baseline 10.23 2.54 41.27 Yes Not Robust Having a higher baseline score increases the chance of having greater acute toxicity
Tissue Category - Bone 1.92 0.39 9.35 No Not Robust
Tissue Category - Air 1.30 0.24 6.98 No Not Robust
Soft tissue fibrosis
Cohort 0.93 0.52 1.67 No Not Robust
Baseline 3.32 1.77 6.21 Yes Robust Having a higher baseline score increases the chance of having greater acute toxicity
Tissue Category - Bone 0.97 0.45 2.10 No Not Robust
Tissue Category - Air 0.46 0.20 1.04 No Not Robust
Alopecia
Cohort 1.57 0.87 2.82 No Not Robust
Baseline 5.10 1.72 15.14 Yes Not Robust Having a higher baseline score increases the chance of having greater acute toxicity
Tissue Category - Bone 4.90 1.95 12.36 Yes Robust Patients with a bone treatment site have a increased chance of having greater acute toxicity
Tissue Category - Air 1.59 0.61 4.15 No Not Robust
Skin ulceration
Cohort 0.87 0.41 1.85 No Not Robust
Baseline 2.50 0.58 10.70 No Not Robust
Tissue Category - Bone 0.71 0.28 1.82 No Not Robust
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Figure 5.11: Scatter plot (taken from the IBM® SPSS software output) of the raw residuals against 
the predicted probability for the rash adverse event.  
 
Figure 5.12: Scatter plot (taken from the IBM® SPSS software output) of the raw residuals against 





Figure 5.13: Scatter plot (taken from the IBM® SPSS software output) of the raw residuals against 
the predicted probability for the pain adverse event.  
 
Figure 5.14: Scatter plot (taken from the IBM® SPSS software output) of the raw residuals against 





Figure 5.15: Scatter plot (taken from the IBM® SPSS software output) of the raw residuals against 
the predicted probability for the soft tissue fibrosis adverse event.  
 
Figure 5.16: Scatter plot (taken from the IBM® SPSS software output) of the raw residuals against 





Figure 5.17: Scatter plot (taken from the IBM® SPSS software output) of the raw residuals against 
the predicted probability for the skin ulceration adverse event. 
 Adverse event 
Number of outliers 





Soft tissue fibrosis 6 
Alopecia 4 
Skin ulceration 26 
Table 5.9: The number of outliers (i.e. normalised residuals with an absolute value larger than 2.6) 





General patient and treatment characteristics such as age, gender, cancer type, treatment site and 
electron energy were similar in both cohorts, suggesting that the potential for these characteristics to 
act as confounding factors in this statistical analysis is low. The exception is the cancer centre in 
which the patients were treated. A larger percentage of patients was treated at Port Macquarie (47%) 
compared with those treated at the other two centres. While the three cancer centres act across a 
common health network in terms of procedures, cross-site involvement and data sharing, there is still 
the possibility of centre-specific differences in the way that patient acute toxicity data is assessed 
and recorded. Therefore, the potential exists for a small bias in the data. However, this potential bias 
is offset to a large degree by having patients recruited into the study across three different cancer 
centres over a broad geographical area, allowing for a larger and more representative sample of the 
overall population. 
In terms of interpreting and recording patient toxicity information, there may be differences between 
different staff groups (e.g. nurses, radiation therapists or radiation oncologists) and even within staff 
groups (e.g. different radiation oncologists). At the Port Macquarie cancer centre, radiation therapists 
generally perform the baseline toxicity assessment for three out of the seven adverse events (rash, 
pain and infection), while the remaining four adverse events (telangiectasia, soft tissue fibrosis, 
alopecia and skin ulceration) are generally assessed by radiation oncologists. However, not all 
adverse events are always recorded as part of the baseline toxicity assessment, even though it is a 
requirement according to MNCCI procedures. In this statistical analysis, any adverse events that did 
not have a grade recorded as part of the patient baseline toxicity assessment were assumed to be 
zero (i.e. no toxicity). While this assumption is likely to hold in most cases, it may not always be valid, 
as the potential exists for patients to have had an actual baseline toxicity that was either not assessed 




As outlined in the patient eligibility criteria, patients with maximum baseline scores greater than 1 
were not included in this analysis. While this statistical analysis has attempted to account for the 
baseline grade as best as possible (e.g. by using the difference grade in the Cochran-Armitage test 
for linear trend and by including baseline grade as a predictor variable in the binary logistic regression 
models), the rationale for this eligibility criterion was to limit the inclusion of relatively “sick” patients 
in the study and to reduce the number of negative difference grades (which bear little clinical 
meaning). The decision to limit baseline toxicity grades reduced eligible patient numbers by 
approximately 15% for cohort 1 and 10% for cohort 2.  
The Cochran-Armitage test for linear trend did not yield statistically significant results for any of the 
adverse events, or for all adverse events combined. This finding clearly demonstrates that there is 
no statistically significant increase in acute skin toxicity for patients in cohort 2 compared with those 
patients in cohort 1. Therefore, the change in clinical practice from using a 𝐷𝑤-based approach to a 
𝐷𝑚-based approach for MU calculations does not translate into an increase in the NTCP for skin 
cancer patients treated with electrons.  
As discussed in Section 5.2.3, the assumption of linearity and the effect of outliers are two important 
aspects of a valid binary logistic regression model. Two other assumptions are the assumption of 
sufficiently large sample size and the assumption of no multicollinearity (i.e. relatively independent 
predictor variables).  
In terms of sufficient sample size, there is no “hard and fast” rule. However, a general guideline is 
that a minimum of 5 - 10 cases with the least frequent outcome is needed for each variable in the 
model. Overall, the use of a binary logistic regression model helped to increase sample size. 
However, the rash adverse event clearly has insufficient numbers to meet the sample size guideline 




be deemed unreliable. Given that the results of this model were also insignificant, the model 
unreliability does not pose a problem. The issue of small sample size can also be seen, but to a 
lesser extent, for the infection, telangiectasia and skin ulceration adverse events where only 3 - 4 
cases of baseline toxicity were observed. Therefore, the results of these models should also be 
treated with caution.  
The assumption of no multicollinearity can be assessed by ensuring there are relatively identical 
distributions of the binary baseline toxicity scores and the 3-level tissue category values in each 
cohort. While this assumption holds for the majority of models, it does not hold for the infection and 
skin ulceration adverse events (in terms of the baseline toxicity scores). Again, the results of these 
models should be treated with caution.  
While a number of statistically significant results were obtained from the binary logistic regression 
models, the interpretation of the results must consider the various limitations of the models as well 
as the clinical significance of the findings. Given all of the data presented as part of this statistical 
analysis, the final interpretations of the binary logistic regression models are set out in Section 5.4.1 
– Section 5.4.3.  
5.4.1 Baseline toxicity predictor variable 
For multiple adverse events (infection, pain, telangiectasia, soft tissue fibrosis and alopecia), there is 
a statistically significant correlation between baseline toxicity grade and acute toxicity grade. This 
result is not particularly surprising as it suggests that patients who started their treatment with higher 





However, due to the effect of outliers in the dataset, the models are not deemed to be robust in the 
case of the infection, pain, telangiectasia and alopecia adverse events.  
The only statistically significant baseline toxicity result to have a robust model, sufficient sample size 
and where no multicollinearity can be assumed is the soft tissue fibrosis adverse event. In this case, 
it can be said with a high level of confidence that a greater soft tissue fibrosis toxicity score recorded 
at the baseline assessment is likely to result in a higher level of soft tissue fibrosis during treatment 
and in the 90 days following treatment.  
5.4.2 Cohort predictor variable 
There was only one statistically significant correlation between cohort and acute toxicity grade 
observed – this was for the pain adverse event. The model showed that patients in cohort 2 
experienced statistically significant lower levels of pain than those patients in cohort 1. The model 
result was also found to be robust, placing a high degree of confidence in this finding.  
One possible explanation for this finding is that those patients in cohort 2, who, on average, receive 
more MU, may experience a higher TCP, which in turn may lead to them experiencing less pain. 
However, to verify this, studies of patient survival rates would need to be undertaken.  
5.4.3 Tissue category predictor variable 
For both the pain and alopecia adverse events, there is a significant correlation between treatment 
sites involving bone and acute toxicity.  
In the case of the pain adverse event, the model showed that patients with a bone treatment site 




outliers in the dataset, this model result is not robust, and so a relatively lower level of confidence 
should be placed in this finding.  
For the alopecia adverse event, patients with a bone treatment site were found to have statistically 
significant increased levels of alopecia. The model result was also found to be robust, placing a high 
degree of confidence in this finding. This result is not cohort-specific but applies across the full patient 
sample. While this result is statistically significant, it is unclear if it is also clinically significant. 
Increased levels of alopecia for a patient would involve hair loss that may be visible to others, that 
may involve wearing a wig/hair piece to provide camouflage and that may be accompanied by 
psychosocial impact. 
These two significant results demonstrate that the tissue category predictor variable warranted 
inclusion as a predictor variable in the binary logistic regression models. 
5.4.4 Future directions 
This statistical analysis has focused only on acute skin toxicity data to assess the change in clinical 
practice from using a 𝐷𝑤-based approach to a 𝐷𝑚-based approach for MU calculations in electron 
treatments. While this cohort study has shown that there is no statistically significant increase in acute 
toxicity for patients treated with the 𝐷𝑚-based MU as calculated in the Elekta Monaco® eMC 
algorithm, to fully assess the clinical impact to the patient, future studies should investigate the effect 
of the change in clinical practice on both late toxicity and TCP. Studies of late toxicity would involve 
patient follow up over multiple years (often 3 - 5 years), while studies of TCP would require a statistical 
analysis of 5 and 10-year patient survival data (data available in 2024 and 2029 respectively). If future 




a result would further validate the use of 𝐷𝑚-based eMC dose calculations for skin cancer patients 
treated with electron beams.  
5.5 Conclusions 
There is no statistically significant increase in acute skin toxicity for patients in cohort 2 compared 
with those in cohort 1. 
For the infection, pain, telangiectasia, soft tissue fibrosis and alopecia adverse events, there is a 
statistically significant correlation between baseline toxicity grade and acute toxicity grade. This 
finding suggests that baseline grade is often a predictor of acute toxicity grade. 
Patients treated with the 𝐷𝑚-based MU as calculated in the Elekta Monaco® eMC algorithm 
experience statistically significant lower levels of pain, compared with those patients treated with the 
measured 𝐷𝑤-based MU. 





6 Response to research questions 
In this chapter, the two key research questions, framed in Chapter 1, are answered.  
6.1 Response to research question 1 
Research question 1: Are the 𝐷𝑚-based MU as calculated in the Elekta Monaco® eMC algorithm 
accurate in a range of clinically relevant settings? 
The comparison performed between measured and calculated dose found that the Elekta Monaco® 
eMC 𝐷𝑚 calculation was in agreement with measurement for the majority of scenarios considered. 
Specifically, the level of agreement between the measured and calculated 𝐷𝑚 data is mostly within 
± 3.5% for a wide range of tissue types. However, for tissues with densities significantly different from 
water (i.e. < 0.5 g/cm3 and > 1.5 g/cm3), the method used to determine 𝐷𝑚 from measurements of 
ionisation resulted in unacceptable levels of uncertainty. For these tissues, a more accurate validation 
method, such as full Monte Carlo modelling, is required. 
6.2 Response to research question 2 
Research question 2: Is there a clinically observable increase in acute skin toxicity for electron 
patients treated with the Elekta Monaco® eMC 𝐷𝑚-based MU as compared with a similar cohort of 




The results of the cohort study, using the Cochran-Armitage test for linear trend, found no statistically 
significant increase in acute skin toxicity for patients in cohort 2 compared with patients in cohort 1. 
Therefore, the change in clinical practice from using measured 𝐷𝑤-based MU to using the 𝐷𝑚-based 
MU as calculated in the Elekta Monaco® eMC algorithm does not increase acute skin toxicity for skin 
cancer patients treated with electron beams. 
Binary logistic regression modelling found a statistically significant correlation between baseline 
toxicity grade and acute toxicity grade, suggesting that baseline grade is often a predictor of acute 
toxicity grade. This modelling also found that patients treated with the 𝐷𝑚-based MU as calculated 
in the Elekta Monaco® eMC algorithm experience statistically significant lower levels of pain, while 
those patients with treatment sites involving bone experience statistically significant lower levels of 
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